

















A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 




































































Brooke Campbell Matson 










Brooke Campbell Matson: Molecular Regulators of Embryo Implantation and Pregnancy 
(Under the direction of Kathleen Caron)  
 
Embryo implantation is one of the first steps in the establishment of pregnancy and 
sets the stage for proper embryonic and placental development. We are beginning to 
appreciate the complexity of implantation and its demand for synchrony between embryo 
and endometrium. Over the years, many groups have identified and studied both embryonic 
and endometrial factors affecting implantation, but there is still much to learn. Here, we 
focus on the endocrine peptide adrenomedullin (Adm, AM) and its association with female 
reproductive physiology and disease in both mice and humans. 
In Part I, we elaborate on the subfertility phenotype of Adm heterozygous female 
mice by testing whether AM supplementation before implantation can improve fertility and 
pregnancy outcomes. We find that administration of AM directly to the mouse uterus before 
blastocyst transfer enhances implantation success and inter-embryonic spacing. Intra-
uterine delivery of AM also confers morphological and cellular changes to the uterine 
epithelium and stroma that are associated with endometrial receptivity and believed to be 
beneficial for implantation. We also test mid-regional pro-adrenomedullin (MR-proADM), a 
stable surrogate for AM peptide, as a biomarker for endometriosis, which is comorbid with 
infertility. Our studies identify novel mechanisms of action of AM in the endometrium in 
support of implantation and the establishment of pregnancy, providing a foundational basis 
for the use of AM as a clinical therapeutic for infertility. 
In Part II, we address the role of AM in the maintenance of a healthy pregnancy by 
expanding upon previous studies in mouse models with clinical samples from women with 
severe preeclampsia, a placental vascular disorder characterized by hypertension and 
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proteinuria. Because Adm-/- placentas exhibit a preeclampsia-like phenotype, we test the 
hypothesis that MR-proADM concentrations are decreased in plasma from women with 
severe preeclampsia. Indeed, we find that MR-proADM levels are blunted in women with 
severe preeclampsia and that MR-proADM is similarly effective as other established 
biomarkers of preeclampsia at distinguishing between cases and controls. Altogether, our 
studies in both mice and humans point to diagnostic and therapeutic applications for AM in 
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PART I – ESTABLISHMENT OF PREGNANCY 
 
 
Chapter 1: Introduction – Embryo Implantation and Adrenomedullin 
 
 
Embryo Implantation and Endometrial Receptivity 
Proper blastocyst implantation is vital for the establishment of pregnancy and hinges 
upon endometrial receptivity, among many other factors.1,2 Aberrant endometrial receptivity 
is an enigmatic cause of infertility that even “last-line” assisted reproductive technology 
(ART), in vitro fertilization (IVF), cannot overcome.3-5 While endometrial “sub-receptivity” 
may permit implantation, it may also program adverse maternal and fetal outcomes that 
present later in pregnancy.6,7 Unfortunately, very little is understood about the molecular 
mechanisms underlying endometrial receptivity and blastocyst implantation. Therefore, 
many cases of infertility are unexplained and unresolved despite the use of ART.8 Likewise, 
the etiologies of many pregnancy complications are incompletely understood. Advances in 
our understanding of the signaling pathways underlying endometrial receptivity will therefore 
shed light on potential therapeutics for infertility and complications of pregnancy, or 
conversely, on innovative contraceptive methods. 
Receptivity is achieved by a complex dialogue between the blastocyst and the 
epithelial and stromal compartments of the uterus during the peri-implantation period, which 
occurs between embryonic day (e) 0 to e4.5 and shortly thereafter in mice.9-11 At e4.5, the 
blastocyst attaches to the uterine luminal epithelium, and the trophectoderm layer – the 
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outer layer of the blastocyst surrounding the inner cell mass – begins to invade the 
endometrium, the inner lining of the uterus. Concurrently, uterine stromal cells adjacent to 
the implantation site undergo a differentiation process termed decidualization to generate 
decidual cells that provide support to the embryo prior to the development of the placenta.12 
Decidual cells immediately surrounding the embryo organize into a transient, avascular zone 
termed the primary decidual zone (PDZ), which is believed to form a highly selective barrier 
around the embryo to prevent rejection by the maternal immune system.13 
A salient signaling pathway for these processes is the leukemia inhibitory factor-
signal transducer and activator of transcription 3 (LIF-STAT3) axis.14,15 The LIF receptor, via 
Janus kinase (JAK), phosphorylates STAT3, stimulating its translocation into the nucleus 
and the transcription of effector genes.16 Female mice with a global Lif deletion or with a 
pan-uterine or uterine epithelial-specific Stat3 deletion (Stat3d/d) are all infertile due to 
defects in implantation and decidualization.17-19 More specifically, Stat3d/d females 
demonstrate impaired uterine epithelial remodeling during the peri-implantation period due 
in part to aberrant expression and localization of junctional proteins.17 Two downstream 
targets of STAT3 during the pre-implantation period have been identified in the uterus – 
early growth response 1 (Egr1) and epidermal growth factor receptor (EGFR) signaling – but 
others remain to be discovered.17,20 
 
Adrenomedullin and the Establishment of Pregnancy1 
The peptide hormone adrenomedullin (Adm, AM) is a candidate gene target of 
Stat3.21-23 Originally isolated from pheochromocytoma extracts,24 AM is a vasodilatory, 
angiogenic, and anti-inflammatory protein with demonstrated roles in cardiac and lymphatic 
vascular development and tumor biology.25,26 AM belongs to the calcitonin/calcitonin gene-
                                                
1Reprinted in part with permission from: Matson BC & Caron KM. Adrenomedullin and endocrine 
control of immune cells during pregnancy. Cell Mol Immunol. 2014;11:456-459. 
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related peptide (CGRP) family, which binds various combinations of G-coupled protein 
receptors (GPCRs) and their associated receptor activity modifying proteins (RAMPs). The 
canonical receptor for AM is calcitonin receptor-like receptor (Calcrl, CLR) when associated 
with either RAMP2 or 3.27 Estrogen and hypoxia, which are elevated throughout pregnancy, 
dramatically upregulate either Adm or Calcrl gene expression in several human and rodent 
female reproductive tissues including the uterus, ovary, and placenta, thus underscoring the 
significance of AM signaling in female-specific reproductive physiology.28-33 
At the organismal level, plasma concentrations of AM are elevated two-to-three-fold 
above baseline levels in many disease states, such as cardiovascular, hepatic, renal, and 
pulmonary disease, but interestingly, the largest increase in plasma AM levels occurs during 
a healthy pregnancy.34 Whether this physiological elevation occurs during complications of 
pregnancy remains uncertain.35 However, polymorphisms in the human Adm gene are 
associated with preeclampsia,36 and administration of an AM antagonist to pregnant rats 
causes placental and fetal pathologies.37 A newly developed assay to detect a proteolytically 
cleaved precursor of active AM, mid-regional pro-adrenomedullin (MR-proADM), provides an 
alternative way to quantitate AM in humans and is currently being investigated as a 
biomarker of cardiovascular disease, pneumonia, and sepsis.38 While data on changes in 
AM levels in complications of pregnancy have been inconsistent, MR-proADM provides 
hope that consensus about changes in plasma AM levels in reproductive diseases can be 
achieved and may potentially be used as a surrogate for the prognostic determination of 
pregnancy complications.39  
At the cellular level, many studies have described Adm expression in tissues derived 
from both the mother and the fetus: ovary, uterus, placenta, and fetal membranes.40-46 For 
example, just prior to implantation in mice, Adm is highly expressed in the trophectoderm 
cells of the early blastocyst and the luminal epithelial cells of the uterine lining.42,47,48 Shortly 
after implantation, and during the rapid expansion of the murine decidua, Adm expression is 
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strongly centered within the primary decidual zone (PDZ), a 3-5 cell-layer thick region 
surrounding the recently implanted embryo which serves as a temporary and physical 
barrier to immunological attack.48 However, Adm expression is most enriched in mouse 
trophoblast giant cells (TGCs) throughout pregnancy, with approximately 30-fold higher 
levels in differentiated TGCs compared to undifferentiated precursors.48 Because TGCs are 
active players in the processes of implantation, decidualization, and placentation, this robust 
expression of Adm from these fetal cells implicates AM in many stages of pregnancy.49 
Moreover, TGCs of Adm-/- placentas undergo apoptosis, further suggesting that AM is critical 
for the survival of these cells that are central to the maintenance of a healthy pregnancy.50 
During the generation of gene-targeted Adm-/- mice, which are embryonic lethal by 
e14.5,51 it was observed that Adm+/- females had smaller litters than their wild type 
counterparts, prompting questions about the fertility of Adm+/- dams. Subsequently, it was 
demonstrated that wild type expression levels of Adm are important for endometrial 
receptivity in mice during the peri-implantation period, specifically via the promotion of 
pinopode formation – a proxy for endometrial receptivity – in the uterine luminal epithelium.47 
Healthy implantation, however, is likely determined by factors beyond uterine luminal 
epithelium, such as appropriate tempering of maternal immunity.  Based on the interaction 
of AM with its anti-inflammatory binding partner, complement factor H, one could speculate 
that AM is also important for preventing an immune attack on the embryo during the peri-
implantation period.47 
Embryos that are able to implant in Adm+/- uteri do so unevenly both within and 
between uterine horns.48 It is possible that this Adm+/- implantation phenotype is due in part 
to changes in ciliary beat frequency in the oviduct.52,53 Embryos of Adm+/- dams are also 
more likely to die or demonstrate abnormalities symptomatic of poor placental perfusion 
during the development of the placenta between e9.5 and e12.5.48 Furthermore, placental 
morphologies observed in embryos developing within Adm+/- uteri exhibit aberrant invasion 
5 
 
of Adm-expressing TGCs into the decidua.48 Collectively, these studies in Adm+/- female 
mice demonstrate that the expression and dosage of maternal AM is a critical determinant of 
normal endometrial receptivity and proper implantation. These studies also suggest that 
administration of AM directly into the uterus prior to implantation or early pregnancy may 
improve fertility and pregnancy outcomes. In this next chapter, we test this hypothesis and 
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Chapter 2: Adrenomedullin Improves Fertility and Promotes Pinopodes and Cell 




 Implantation is a complex event demanding contributions from both embryo and 
endometrium. Despite advances in assisted reproduction, endometrial receptivity defects 
persist as a barrier to successful implantation in women with infertility. We previously 
demonstrated that maternal haploinsufficiency for the endocrine peptide adrenomedullin 
(AM) in mice confers a subfertility phenotype characterized by defective endometrial 
receptivity and sparse epithelial pinopode coverage. The strong link between AM and 
implantation suggested the compelling hypothesis that administration of AM prior to 
implantation may improve fertility, protect against complications, and ultimately lead to better 
maternal and fetal outcomes. Here, we demonstrate that intrauterine delivery of AM prior to 
blastocyst transfer improves the embryo implantation rate and spacing within the uterus. We 
then use genetic decrease-of-function and pharmacologic gain-of-function mouse models to 
identify potential mechanisms by which AM confers enhanced implantation success. In 
epithelium, we find that AM accelerates the kinetics of pinopode formation and water 
transport, and in stroma, that AM promotes connexin 43 expression, gap junction 
communication, and barrier integrity of the primary decidual zone. Ultimately, our findings 
advance our understanding of the contributions of AM to endometrial receptivity and suggest 
                                                
1Adapted with permission from: Matson BC, Pierce SL, Espenschied ST, Holle E, Sweatt IH, Davis 
ES, Tarran R, Young SL, Kohout TA, van Duin M & Caron KM. Adrenomedullin improves fertility and 




potential broad use for AM as therapy to encourage healthy embryo implantation, for 
example in combination with in vitro fertilization. 
 
Introduction 
 Blastocyst or embryo implantation is essential for the establishment of pregnancy 
and occurs during the window of implantation between embryonic days (e) 3.5-4.5 in mice 
and between days 6-12 post-fertilization in humans.1 While embryo implantation takes place 
during the very early days of pregnancy, errors occurring during this process can program 
clinical complications of pregnancy that present later in gestation, leading to adverse 
maternal and fetal outcomes.2 A complex dialogue between the embryo and the 
endometrium coordinates this delicate and precisely timed event, offering two angles from 
which to approach the clinical problem of infertility, which affects millions of women and 
families across the world.3,4 Modern assisted reproductive technology (ART) can address 
embryonic defects preventing implantation and the establishment of pregnancy by screening 
embryos for aneuploidy. However, in women, only about half of the euploid blastocysts 
transferred to the endometrial cavity in an optimally prepared uterus result in a successful 
pregnancy, underlining the inability of current medical techniques to alter endometrial 
receptivity and the need for development of improved therapies.5 
 Both the embryo and the uterus express cell surface molecules that enable their 
physical interaction, facilitating apposition and attachment of the blastocyst to the uterine 
luminal epithelium. Following closure of the epithelium around the embryo, embryonic 
trophoblast cells breach this layer by entosing living epithelial cells.6 While the luminal 
epithelium is the first cell type that comes into direct contact with the embryo, uterine stromal 
cells also play a large role during the peri-implantation period. Stromal cells surrounding the 
implantation crypt undergo a progesterone-driven differentiation process termed 
decidualization that enable these cells to provide support to the embryo prior to the 
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development of a placenta.7 A subpopulation of decidualized stromal cells adjacent to the 
embryo coordinate the formation of a transient, avascular region called the primary decidual 
zone (PDZ), which has been hypothesized to form a highly selective barrier that protects the 
embryo from immunological attack.8 Despite advances in our understanding of these peri-
implantation events in recent years, there is still much to be discovered about the molecular 
mechanisms underlying endometrial receptivity and implantation. 
 Previously, we and others established the peptide hormone adrenomedullin (Adm 
gene, AM protein) as an endocrine factor derived from both the mother and the fetus that is 
important for implantation, placentation, and the overall health of a pregnancy.9,10 Notably, 
female mice heterozygous for Adm display a subfertility phenotype, demonstrating 
decreased pregnancy success and decreased epithelial pinopode coverage.11,12 Litters of 
Adm+/- dams demonstrate irregular embryonic spacing and crowding in utero as well as fetal 
growth restriction and loss, yielding smaller litter sizes at weaning.12 However, the cellular 
and molecular pathways downstream of AM peptide in the uterus remain to be elucidated. 
 During the peri-implantation period, Adm is spatiotemporally co-expressed with 
components of adherens junctions, tight junctions, and gap junctions in luminal epithelium 
and in decidualized stroma.11,13-15 Notably, aberrant junctional protein expression and 
localization in these compartments can cause problems during implantation and 
decidualization with implications for fertility. For example, conditional deletion of several 
different transcription factors alters endometrial receptivity by interfering with expression of 
the tight junction protein claudin-1 (Cldn1 gene, CLDN1 protein).16-18 Furthermore, 
decreased connexin 43 (Gja1 gene, Cx43 protein) function via a dominant loss-of-function 
mutation or administration of a pharmacological inhibitor interferes with early implantation 




 Given the spatiotemporal co-expression of Adm and cell junction proteins in the 
uterus during peri-implantation, AM may promote cell- and tissue-level organization by 
affecting junctional proteins. For example, in vitro studies on lymphatic endothelium 
previously demonstrated that AM induces organization of VE-cadherin and ZO-1.21 We also 
found that AM promotes Cx43 mRNA and protein expression; Cx43 plasma membrane 
linearization; and gap junction coupling and intercellular communication, all in lymphatic 
endothelial cells.22 By extension, this precedent for an AM effect on cell junctions may also 
apply to other cell types, which we evaluate in this current study. When taken together, the 
subfertility phenotype of Adm+/- dams and evidence for AM-cell junction interactions suggest 
the compelling hypothesis that AM promotes cell junction integrity in epithelial and stromal 
cells of the uterus, supporting the early embryo during an active time of complex tissue 
remodeling and thereby bolstering fertility. Here, we test this hypothesis and demonstrate 
that AM improves implantation success and spacing in mice and promotes cell junction 
organization in the peri-implantation uterine epithelium and stroma. 
 
Materials and Methods 
Animals 
 Mice with a deletion of the Adm gene were previously described and were 
maintained as a heterozygote colony on an isogenic 129S6/SvEv background.23 Genotyping 
was performed using three primers – primer 1: 5′-CAGTGAGGAATGCTAGCCTC-3′; primer 
2: 5′-GCTTCCTCTTGCAAAACCACA-3′; primer 3: 5′-TCGAGCTTCCAAGGAAGACCAGG-
3′. Primers 1 and 3 amplify the wild type allele (1.8 kb), while primers 2 and 3 amplify the 
targeted allele (1.3 kb). All animal experiments were approved by the University of North 




 Wild type CD1 female mice at least 8 weeks old (Charles River) were mated with 
vasectomized CD1 IGS males (Charles River) to generate pseudopregnant females. The 
morning of the vaginal plug was designated pseudopregnant day 0.5. On pseudopregnant 
day 2.5, e3.5 blastocysts were collected from superovulated C57BL/6 donor females 
(Envigo). Immediately prior to blastocyst transfer, 0.9% NaCl or 150 pmol AM (4.3 μl) 
(Phoenix Pharmaceuticals) was injected directly into each horn of the uterus of 
pseudopregnant females anesthetized with tribromoethanol (0.4 mg/g body weight). AM was 
co-injected with AM(24-50) (6.15 μl total) (Phoenix Pharmaceuticals) at a 20:1 AM(24-
50):AM molar ratio or with complement factor H (CFH) (5.73 μl total) (R&D Systems) at a 
3.3:1 CFH:AM weight ratio. Eight blastocysts were transferred into uterine horns treated with 
AM or AM + AM(24-50), and 16 blastocysts were transferred into uterine horns treated with 
AM + CFH. Recipient females were euthanized three days later after a tail vein injection of 
0.1 mL 1% Evans blue dye (Sigma-Aldrich) in 0.9% NaCl. Embryo spacing was calculated in 
ImageJ (NIH) using the quantitation method depicted in Figure 2-1C. 
In vivo barrier permeability assay 
 Wild type and Adm+/- females at least 8 weeks old were used for timed pregnancies. 
Visualization of the vaginal plug was considered e0.5. On e7.5, mice were anesthetized with 
tribromoethanol and injected retro-orbitally with 1 mg biotinylated bovine serum albumin 
(BSA). Two hours after injection, mice were euthanized, and implantation sites were 
dissected and fixed overnight in 4% paraformaldehyde at 4°C. Following fixation, 
implantation sites were cryoprotected in 30% sucrose and frozen in optimal cutting 
temperature (OCT) compound for sectioning. Tissue sections were stained with 




 Day 2.5 pseudopregnant females were treated with a direct intrauterine injection of 
0.9% NaCl or 150 pmol AM (4.3 μl) (Phoenix Pharmaceuticals). Thirty minutes later, animals 
were euthanized and dissected. A segment of uterine tissue was weighed at the time of 
dissection, incubated in a 60°C oven for 72 hours, and then re-weighed. 
Optical projection tomography 
 After fixation in 4% paraformaldehyde, e5.0 implantation sites were transferred to 
PBS/0.1% Triton X-100 (PBST) and washed overnight at 4°C. Implantation sites were then 
boiled for 10 minutes in 10 mM citric acid/0.05% Tween 20 and allowed to cool to room 
temperature. Tissue was subsequently washed at room temperature for 5 minutes in PBST, 
5 minutes in ddH2O, 7 minutes in ice cold acetone, 5 minutes in ddH2O, and 5 minutes in 
PBST. The tissue was then blocked overnight at 4°C in 5% normal donkey serum/1% 
BSA/1% DMSO in PBST. Samples were incubated at 4°C for one week in primary 
antibodies: Cx43 (1:200, Sigma-Aldrich) and FITC-conjugated IB4 lectin (1:100, Sigma-
Aldrich) diluted in blocking solution. Samples were washed 7 x 15 minutes + 1 hour in 1% 
BSA/1% DMSO in PBST then incubated for 90 minutes in blocking solution. Secondary 
antibody (DyLight 594 donkey anti-rabbit, 1:100, Jackson ImmunoResearch) was diluted in 
blocking solution, and specimens were incubated for 3 days at 4°C. Tissues were then 
washed 8 x 15 minutes, transferred to PBST and washed overnight. Briefly, to prepare 
samples for OPT scanning, implantation sites were embedded in 1% low-melt agarose and 
dehydrated overnight in methanol at room temperature. Embedded specimens were 
rendered optically transparent by incubating them in benzyl alcohol and benzyl benzoate 
(BABB) for 48 hours before being scanned in a BiOPTonics 3001M Optical Projection 
Tomography Scanner equipped with Cy2 and Texas Red filter sets. 
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Scanning electron microscopy 
 Uterine horns of wild type CD1 females at least 8 weeks old (Charles River) were 
injected with 0.9% NaCl; 150 pmol AM; or 150 pmol AM + 3 nmol AM(24-50) on 
pseudopregnant day 2.5. At the time points specified in Figure 2-4, the animals were 
euthanized, and the uteri were dissected and cut open longitudinally. Uteri were submerged 
in a fixative containing 2% paraformaldehyde/2.5% glutaraldehyde/0.15 M sodium 
phosphate, pH 7.4 and stored at 4° overnight to several days before processing. After 
several washes in buffer, the samples were dehydrated through an ethanol dilution series 
(30%, 50%, 75%, 90%, 100%, and 100%) and subsequently dried using a Samdri-795 
critical point dryer (Tousimis Research Corporation) with liquid carbon dioxide as the 
transition solvent. The tissue was then mounted onto aluminum scanning electron 
microscopy stubs with carbon adhesive tabs and was sputter coated with gold:palladium 
alloy (60:40) to a thickness of 20 nm using a Hummer X Sputter Coater (Anatech, Ltd.). 
Specimens were visualized with a Zeiss Supra 25 field emission scanning electron 
microscope (Carl Zeiss SMT) using an accelerating voltage of 5 kV. Quantitation of 
pinopode number, size, and percent area were performed in ImageJ (NIH). Images were 
batch processed with a macro that binarized, inverted, eroded, and then analyzed each 
image for particles greater than 0.2 μm in area and with a circularity between 0.3-1.00. 
Alternatively, pinopode number was manually determined using an ImageJ Cell Counter 
plugin. 
Immunofluorescence 
 Paraffin-embedded tissues were sectioned, deparaffinized, and hydrated. Following 
antigen retrieval in 10 mM citric acid/0.05% Tween 20, pH 6.0, tissues were permeabilized 
and blocked in 5% normal donkey serum. Slides were then incubated overnight at room 
temperature with primary antibodies: CLDN1 (1:500, Bioworld) or Cx43 (1:200, Sigma-
Aldrich). The following day, tissues were washed, blocked, and incubated in the dark for 1-2 
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hours at room temperature in secondary antibodies: donkey anti-rabbit Cy3 (1:200, Jackson 
ImmunoResearch) or donkey anti-rabbit 594 (1:200, Jackson ImmunoResearch). Stained 
tissues were imaged on a Nikon E800 fluorescence microscope with an Orca CCD camera 
(Hamamatsu) and Metamorph software (Molecular Devices). 
Cell culture 
 Ishikawa cells were incubated at 37°C containing 5% CO2 and cultured in phenol 
red-free DMEM/F12 (Gibco) + 10% fetal bovine serum (FBS) + 1x penicillin/streptomycin. 
Ishikawa cells transepithelial resistance was determined used an epithelial volt/ohm meter 
(World Precision Instruments). The collection of primary human endometrial stromal cells 
(hESCs) from consenting healthy women was approved by the University of North Carolina 
at Chapel Hill Institutional Review Board. Human ESCs were incubated at 37°C containing 
5% CO2 and cultured in DMEM/F12 (Gibco) + 10% FBS + 1x penicillin/streptomycin. Human 
ESCs were artificially decidualized for 5 days in DMEM/F12 + 2% FBS + 1x 
penicillin/streptomycin + 0.5 mM 8-Br-cAMP (Sigma-Aldrich) + 1 μM medroxyprogesterone 
17-acetate (Sigma-Aldrich). 
Water permeability assay 
 Ishikawa cells were plated on collagen-coated 12 mm transwells with 0.4 μm pores 
(Corning) and grown to confluency. Water permeability was measured as previously 
described.24 In brief, Ishikawa cells were incubated with 3 μM calcein-AM (ThermoFisher) for 
30 minutes prior to pre-treatment with a vehicle control or 10 nM AM (American Peptide 
Company/Bachem) for one hour. Ishikawa cultures were then placed in an Attofluor® Cell 
Chamber with 100 μL of modified Ringer solution added serosally [101 mM NaCl, 12 mM 
NaHCO3, 24 mM HEPES, 1.2 mM MgCl2, 1.2 mM CaCl2 ∙ 2H2O, 5.2 mM KCl, 10 mM D-(+)-
Glucose (Sigma)]. 100 μL of isotonic Ringer solution was added apically and a baseline 
image obtained. After apical addition of 100 μL of Ringer solution containing an additional 
150 mM NaCl (600 mOsm total osmolarity), cultures were imaged on a Leica SP5 confocal 
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microscope over a 30 second period using a 40x water immersion lens (0.9 NA) with calcein 
excited at 488 nm. Cell height and fluorescence were measured in ImageJ (NIH), and linear 
regression was performed on the percent change in cell height and fluorescence over time 
after addition of hypertonic buffer. 
Ussing chamber studies 
 Confluent Ishikawa cultures in collagen-coated 12 mm Snapwell inserts with 0.4 μm 
pores (Corning) were pre-treated with a vehicle control or 10 nM AM (American Peptide 
Company/Bachem) before being mounted in Ussing chambers (Physiologic Instruments). 
Data was collected with Acquire and Analyze software (Physiologic Instruments). Cultures 
were bathed in 5 mL of isotonic 37°C Krebs-Ringer bicarbonate buffer circulated with 95% 
O2-5% CO2 gas on both apical and basolateral sides. Cultures were voltage-clamped and 
short circuit current (ISC) and transepithelial resistance (TER) were measured at baseline 
and after addition of 100 μM amiloride apically, 10 μM forskolin apically and basolaterally, 10 
μM CFTR inhibitor-172 apically, and 10 μM UTP apically (Sigma-Aldrich). 
Scrape loading assay 
 Human ESCs were plated in a 6-well plate, grown to confluency, and artificially 
decidualized as described above. Human ESCs were treated with water, 10 nM AM 
(American Peptide Company/Bachem), 100 μM carbenoxolone (Sigma-Aldrich), or 10 nM 
AM + 100 μM carbenoxolone for 30 minutes. Lucifer yellow (Sigma-Aldrich) was added to 
each well to a final concentration of 0.05%. Decidualized hESC monolayers were then 
scraped with a 27 gauge needle, incubated at 37°C for 30 minutes, and then fixed in 4% 
paraformaldehyde for 20 minutes. Cells were then washed and stored in PBS for imaging on 
an Olympus IX81 (Olympus). Images were analyzed in ImageJ (NIH) by measuring the 
distance from the scratch to the farthest lucifer yellow dye-positive nucleus in the field. 
Images were converted to black and white and then inverted in ImageJ for publication. All 




 All data are presented as mean ± SEM unless otherwise noted. All statistics were 
performed in Prism 5 (GraphPad Software, Inc.). Implantation sites per horn following 
blastocyst transfer were compared by Mann-Whitney test, as the AM-treated group fails the 
Shapiro-Wilk test of normality. Embryo spacing was analyzed by unpaired t-test with Welch’s 
correction, as the vehicle-treated group has a very wide dispersion compared to the other 
two groups. Pinopode number, size, and density were significantly different by Kruskal-
Wallis test, but unpaired t-tests are displayed to emphasize abrogation of the AM effect by 
co-treatment with its inhibitor, AM(24-50). The pinopode time course was analyzed by two-
way ANOVA followed by Bonferroni post-tests. Uterine wet:dry weight; Ishikawa cell short-
circuit current; distance traveled by lucifer yellow dye in the scrape loading assay; and 
percent penetration to the embryo in the PDZ barrier permeability assay were compared by 
unpaired t-tests, as we did not necessarily expect large effect sizes. Ishikawa cell 
transepithelial resistance (TER) over time in culture was analyzed by two-way ANOVA 
followed by Bonferroni post-tests. If p<0.05, data sets were considered statistically different. 
 
Results 
AM treatment improves implantation success and spacing 
 Given the subfertility of Adm+/- female mice, we first tested whether treating the 
uterus with AM could support implantation and early pregnancy using an in vitro fertilization 
(IVF) embryo transfer model. We treated the uterus of wild type female mice with AM 
immediately prior to blastocyst transfer and observed a significant increase in the 
implantation numbers between vehicle- and AM-treated animals at e6.5, an effect that was 
reversed by co-treatment with the mouse AM inhibitor AM(24-50) (Figure 2-1A and B). We 
then attempted to bolster the effect of AM by co-treating with its binding partner, 
complement factor H (CFH), as has been done by other groups in the context of sepsis 25,26. 
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However, we found that co-treatment of AM and CFH was antagonistic to implantation and 
led to fewer viable implantation sites at e6.5 compared to vehicle-treated animals (data not 
shown). 
Our previously published embryonic spacing defect in the Adm+/- sub-fertile female 
mice then prompted us to compare the spacing patterns of embryos of vehicle- and AM-
treated animals.12 To quantify embryonic spacing, we calculated the standard deviation of 
distances between the implant sites within each uterine horn (Figure 2-1C). Using this 
method, we found that the standard deviation was significantly lower in AM-treated uterine 
horns, indicating that these embryos were more evenly spaced relative to each other 
compared to their vehicle-treated counterparts (Figure 2-1D). 
AM promotes epithelial pinopode formation 
We then analyzed the luminal epithelium of vehicle- and AM-treated uteri for the 
presence of pinopodes: spherical protrusions of the epithelial plasma membrane into the 
lumen of the uterus that are present in mice and humans during the window of implantation 
and associated with endometrial receptivity.27 We previously discovered that the epithelial 
surfaces of Adm+/- uteri present fewer pinopodes, underscoring our rationale for investigating 
AM-mediated effects on pinopode dynamics.12 Scanning electron microscopy (SEM) 
enabled visualization of pinopodes as large as 10 μm in diameter even at low magnification 
(Figure 2-2A). At higher power, many smaller pinopodes of approximately 1 μm in diameter 
were visible in areas surrounding larger pinopodes (Figure 2-2B). Interestingly, we observed 
three-dimensional structures that were similarly sized as pinopodes but appeared collapsed 
or degenerate, raising the compelling possibility that these structures are pinopodes 
captured in various stages of formation or regression (Figure 2-2B, arrow). On the horizon of 
a plane orthogonal to the uterine luminal epithelial landscape, we captured the topography 
of pinopodes protruding prominently above the epithelial surface (Figure 2-2C). Upon closer 
inspection of a single, large pinopode, we again noted several smaller pinopodes in its 
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shadow as well as larger degenerate pinopodes in the surrounding area (Figure 2-2D, 
arrows). We were also able to visualize other ultrastructural features of the epithelium, such 
as cell-cell borders and small, rod-like microvilli (Figure 2-2D, arrowheads and asterisks). 
 We then analyzed the direct effect of AM on pinopode formation by performing a time 
course study, treating wild type pseudopregnant uteri for 30 minutes, 2 hours, 6 hours, or 24 
hours. A 30 minute treatment of the uterus with AM significantly enhanced pinopode number 
as well as pinopode size (Figure 2-3A-C). Ultimately, a significantly larger percentage of the 
epithelial surface was covered by pinopodes in AM-treated uteri compared to vehicle-treated 
uteri (Figure 2-3D). We observed a complete reversal of these AM-mediated changes by co-
treating with AM and its inhibitor, AM(24-50) (Figure 2-3A-D). 
 Quantitation of pinopode density beyond the 30 minute time point revealed a 
common pinopode formation and regression pattern between days 2.5-3.5 of 
pseudopregnancy: first, an enhancement of pinopode number between 2-6 hours, followed 
by a decline between 6-24 hours, and eventually returning to levels comparable to those at 
30 minutes (Figure 2-4A). However, in the AM-treated uteri, we observed an early leftward 
shift of this curve, demonstrating the ability of AM to acutely stimulate pinopode dynamics 
during early pregnancy (Figure 2-4B). There was a statistically significant interaction 
between the effects of time and treatment on pinopode number by two-way ANOVA 
(p=0.003), and Bonferroni post-tests identified significant differences in pinopode number 
after 30 minutes and 6 hours of treatment. 
AM accelerates uterine water transport across the epithelium  
While little is understood about the dynamics of pinopode formation and function, 
several groups have proposed that pinopodes pinocytose uterine fluid.28,29 Therefore, to 
determine whether AM-mediated pinopode formation was associated with enhanced uterine 
water transport in vivo, we treated wild type pseudopregnant uteri with AM and measured 
uterine wet:dry weight. We compared vehicle- and AM-treated uteri and, consistent with our 
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hypothesis, found that the wet:dry weight ratio was significantly higher in AM-treated uteri 
(Figure 2-5A). 
We then asked whether AM enhanced the uterine wet:dry weight ratio by altering 
epithelial ion transport or epithelial water permeability and subsequent water transport using 
Ishikawa cells, which are derived from an endometrial adenocarcinoma and display a hybrid 
phenotype between uterine glandular and luminal epithelium.30,31 Ishikawa cells form 
confluent monolayers and express an array of epithelial-specific proteins, including 
keratins,32 integrins,33 and tight junctions such as claudin 1 (Cldn1, CLDN1) (data not 
shown). Furthermore, Ishikawa cells generate an average transepithelial resistance (TER) of 
approximately 350 Ω after four days in culture, implying a phenotype between leaky and 
tight epithelia and capacity for both paracellular and transcelluar transport (Figure 2-5B).34 
We first performed Ussing chamber studies in Ishikawa cells to assess effects on ion 
transport by measuring changes in epithelial short-circuit current (ISC) and transepithelial 
resistance in response to AM and the following channel modulators: amiloride, an epithelial 
sodium channel (ENaC) inhibitor; forskolin, which induces cAMP activation of the cystic 
fibrosis transmembrane conductance regulator (CFTR); CFTR inhibitor-172; and UTP, an 
activator of calcium-activated chloride channels. Pre-treatment of Ishikawa cells with AM did 
not affect changes in ISC and TER in response to this series of ion channel activators and 
inhibitors, indicating that AM does not affect uterine water balance by altering ion transport 
(Figure 2-5C and D). Notably, modulation of CFTR activity conferred negligible changes in 
ISC and TER, which is consistent with low expression of CFTR in Ishikawa cells (data not 
shown). 
We then assessed whether AM affects water permeability of the Ishikawa cell apical 
membrane by confocal microscopy. Following addition of a hypertonic buffer solution on the 
apical Ishikawa membrane to create an osmotic gradient, we observed a significant 
enhancement in the rate of both Ishikawa cell shrinkage and calcein fluorescent 
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intensification with AM pre-treatment compared to vehicle pre-treatment, indicating that AM 
enhances the rate of water transport across the apical surface of Ishikawa cells (Figure 2-5F 
and G). Altogether, these data support a role for AM in primary water transport, but not ion 
transport, in the uterus. 
AM ensures appropriate epithelial CLDN1 localization 
The junctional protein CLDN1 plays essential roles in water homeostasis in epithelial 
barriers. For example, genetic deletion of Cldn1 in mice confers lethality by post-natal day 1 
due to defective epidermal barrier formation and consequent water loss.35 Previously 
published associations between epithelial cell junction integrity and fertility prompted us to 
examine the localization of CLDN1.16,18 Therefore, we employed our murine model of Adm 
haploinsufficiency and subfertility to investigate the effect of AM on CLDN1 localization in 
the pregnant uterine epithelium. In wild type pregnant uteri, we observed continuous CLDN1 
expression from the apical to the basolateral sides of the lateral membranes of epithelial 
cells. However, in Adm+/- pregnant uteri, we noted collapse of CLDN1 to the basolateral side 
of the lateral epithelial membranes (Figure 2-6). In all animals of both genotypes, we 
observed circumferentially patchy expression of CLDN1 around the lumen. These data 
indicate that even a modest change in the local production of AM in the uterus can influence 
the localization of epithelial barrier proteins during the peri-implantation period. 
AM enhances stromal gap junction communication and barrier integrity 
We next turned our attention to uterine stroma, which includes the primary decidual 
zone (PDZ) adjacent to the embryo as an additional site of robust Adm and cell junction 
expression during the peri-implantation period.11 Decidualized stromal cells communicate 
with each other to organize this complex, three-dimensional structure, which provides an 
early protective barrier to promote successful implantation. Accordingly, we confirmed that 
the gap junction protein Cx43, which facilitates inter-cellular communication, is highly 
expressed in the early implantation site using three-dimensional optical projection 
24 
 
tomography (Figure 2-7A and B). To assess the direct effect of AM on Cx43 in uterine 
stroma, we treated pseudopregnant uteri with AM and performed immunohistochemistry for 
Cx43, finding that AM treatment enhanced Cx43 expression in stroma adjacent to the 
luminal epithelium – the future site of the PDZ (Figure 2-7C).  
We then functionally evaluated whether AM could influence gap junction coupling 
between stromal cells by using primary human endometrial stromal cells (hESCs) to perform 
a scrape loading assay. In this assay, cells are “scratched” open, and the distance of 
transfer of a gap junction-permeable dye, lucifer yellow, is measured across the monolayer. 
Interestingly, AM promoted functional gap junction coupling between hESCs as evidenced 
by the enhanced distance of lucifer yellow dye transfer across the cell monolayer. This effect 
was abrogated by co-treatment with the gap junction inhibitor carbenoxolone (Figure 2-7D 
and E). 
We hypothesize that communication between stromal cells via gap junctions 
provides cues that direct the formation of the PDZ, which forms a selective barrier around 
the embryo. Therefore, given the effect of AM on cellular communication, we assessed the 
consequences of a reduction in AM peptide on the selectivity of this barrier in vivo. We 
examined the integrity of the PDZ in wild type and Adm+/- female mice by injecting pregnant 
mice retro-orbitally with biotinylated bovine serum albumin (BSA) and then assessing the 
depth of BSA penetration into the decidua toward the embryo on two different axes of the 
implantation site. In Adm+/- females, BSA penetrated significantly closer to the embryo 
compared to wild type animals, indicating compromised PDZ barrier function in 
heterozygous decidua (Figure 2-7F and G). Altogether, these data serve as evidence for a 
role for AM in stromal cell communication and PDZ barrier formation in support of early 






 Here, we have elucidated molecular and cellular effects of AM on the epithelial and 
stromal compartments of the uterus during the peri-implantation period. Moreover, we 
demonstrate that administration of AM directly into the uterus enhances the embryo 
implantation rate in mice after blastocyst transfer, suggesting a potential use for AM peptide 
in the context of embryo transfer or IVF in humans.  
There is intense interest in improving the IVF live birth rate, which currently stands at 
less than 50%. Advances in clinical embryology have enabled the identification of aneuploid 
embryos prior to transfer, but the IVF live birth rate remains low because we do not 
completely understand uterine factors supporting implantation. Despite this lack of 
understanding, attempts have been made to overcome endometrial receptivity defects. For 
example, systemic G-CSF treatment has been shown in a single randomized controlled trial 
to benefit women with recurrent implantation failure but not provide benefit to other 
women.36 Endometrial scratching, in which the endometrium is physically injured to provoke 
an inflammatory response, is currently being recommended by practitioners in some 
countries to many women refractory to IVF.37 However, the mechanisms of action following 
this invasive procedure remain unclear. Furthermore, inflammation, if uncontrolled, may be 
associated with abnormal implantation and pregnancy complications.38 Therefore, direct, 
short-term treatment of the endometrium with AM peptide may provide an attractive and 
more efficacious alternative to either a systemically administered drug or an inflammation-
provoking injury. 
Unexpectedly, we found that co-administration of AM and CFH, which binds and 
stabilizes AM in plasma, was antagonistic to embryo implantation.39 In addition to 
associating with AM, CFH blocks activation the alternative complement pathway, deterring 
aberrant complement deposition by facilitating the distinction between self and non-self 
cells.40 Unfortunately, very little is known about the role of complement in embryo 
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implantation and the establishment of pregnancy. Recently, two groups found that activation 
of complement is associated with embryo loss in both mice and humans.41,42 As we begin to 
appreciate the pro-inflammatory environment of embryo implantation, we believe it is 
possible that exogenous administration of high levels of CFH caused dysregulation of fine-
tuned, physiological complement and inflammatory responses that are critical for 
implantation success.43 
Notably, in our study, AM improved not only the implantation rate but also the 
spacing between embryos in utero. How embryos space within the mouse uterine horn is 
not completely understood and, at first glance, appears irrelevant for singleton human 
pregnancies.44 However, what we learn about embryo spacing can certainly inform our 
understanding of embryo-uterine interactions and the choice of implantation location, which 
are highly relevant for both singleton and multi-fetal gestations, especially given the 
programming of clinical complications of pregnancy by implantation defects.2 
Subsequently, we found that AM treatment of the uterus promotes pinopode 
formation, size, and epithelial surface coverage. Only a handful of descriptive studies 
provide information on pinopodes, with the average mouse pinopode quantified at 
approximately 6 μm in diameter.45 Indeed, we identified pinopodes at least 6 μm in diameter, 
but the majority of pinopodes we observed were approximately 1 μm in diameter. These 
differences in size could be explained by differences in genetic backgrounds, by 
visualization of the uterus at different time points during pregnancy, or by different effects of 
pseudopregnancy. We frequently observed what appeared to be ruptured pinopodes in 
various stages of growth or regression. Ruptured pinopodes have been observed in both 
rodents and humans, but more frequently in the latter species.46,47 Other groups have 
argued that pinopode coverage of the epithelium ranges from 0.6% to 20%;45 our studies 
were consistent with these findings. 
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Pinopodes may pinocytose uterine fluid, ultimately affecting uterine water balance in 
support of implantation, though this hypothesis has been largely supported in rats and less 
so in humans.28,29,48,49 We found that AM accelerated water loss across the apical Ishikawa 
cell membrane in the context of hypertonic stress, suggesting that AM renders the apical 
Ishikawa cell membrane more permeable to water. Early in the peri-implantation period, 
uterine water imbibition causes an estrogen-induced accumulation of water in the uterine 
lumen via the transcellular pathway, ultimately changing luminal fluid viscosity to facilitate an 
environment amenable to implantation; this occurs in part by altering aquaporin expression 
and availability50-52 In the mouse, expression of aquaporins-2, -3, and -4 has been observed 
in uterine luminal epithelium, suggesting that these aquaporins may participate in the 
accumulation of water in the uterine lumen.51,52 However, at the time of implantation, water 
transport also occurs in the opposite direction at the time of closure of the uterine epithelium 
around an implanting blastocyst.53 Therefore, water transport across the uterine luminal 
epithelium occurs bidirectionally during the peri-implantation period.   
Our findings of enhanced uterine wet:dry weight and accelerated water transport 
across Ishikawa cells with AM treatment show that AM may contribute to this water transport 
to promote implantation. In further support of this idea, estrogen is a potent regulator of 
uterine water transport, aquaporins, and Adm gene expression – both directly through 
estrogen response elements in the 5’ untranslated region and indirectly through an 
estrogen-induced cohort of miRNAs targeting the 3’ untranslated region of the Adm 
gene.54,55. Given the uterine wet:dry weight data, it is likely that AM stimulates water 
transport from the uterine lumen to the uterine wall, possibly through pinopodes, although 
the tissue compartments in which this water accumulates have yet to be determined. The 
uterine wet:dry weight may also be explained in part by effects of AM on circulatory and 
lymphatic vascular systems, but the direct vascular effects on the uterus in our AM-
supplemented blastocyst transfer model are currently unknown.  
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Given the lethal water loss phenotype of mouse embryos lacking the tight junction 
protein CLDN1, we utilized our sub-fertile Adm+/- mice to investigate the effect of AM on 
CLDN1 localization in the uterine epithelium. Analysis of sub-fertile Adm+/- uterine epithelium 
suggested a role for AM in appropriate localization of CLDN1. Notably, this is not the first 
association between aberrant cell junctional protein expression and localization and 
endometrial receptivity defects. An epithelial-specific deletion of Stat3 and a pan-uterine 
deletion of Msx1/Msx2 on day 4 of pregnancy or pseudopregnancy, respectively, both 
demonstrate anomalous CLDN1 expression and infertility.16,18 More specifically, in each of 
these transcription factor loss-of-function studies, CLDN1 was persistently expressed in 
epithelium, while it was absent in floxed control animals. Therefore, Pawar and colleagues 
concluded that the repression of Cldn1 facilitates a requisite loss of cell polarity during early 
implantation.16 Our observations of aberrant CLDN1 localization in epithelium heterozygous 
for Adm support a role for AM – likely through second messenger signaling – in epithelial 
cell organization, which has consequences for endometrial receptivity and epithelial 
remodeling during implantation. 
In the present study, we also investigated effects of AM on uterine stroma during 
peri-implantation, concluding that AM promotes Cx43 expression in the uterus, stromal 
intercellular communication, and organization of the PDZ. Our conclusion concerning the 
effect of AM on Cx43 expression is consistent with our previously published study in 
lymphatic endothelium.22 The importance of Cx43 and gap junction-mediated intercellular 
communication in the uterus is highlighted by the effects of conditional knockout of Cx43 in 
the uterus, which negatively affects decidualization, expression of angiogenic factors, and 
placental angiogenesis, ultimately leading to fetal loss.56 Furthermore, Adm gene expression 
is upregulated two-fold in stroma from Msx1d/d//Msx2d/d uteri, possibly in a compensatory 
fashion to support the implantation defects in these animals.18  
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Together, the effects of AM on pinopodes, water permeability, and cell junctions in 
the epithelial and stromal compartments of the uterus during peri-implantation synergize to 
support implantation, as evidenced by our finding that treatment of the mouse uterus with 
AM prior to blast transfer improves the implantation rate. This discovery complements 
elegant studies performed by Yallampalli and colleagues in rats, finding that continuous 
administration of the human AM inhibitor, AM(22-52), via osmotic mini-pumps is detrimental 
to implantation and placentation.57,58 Similarly, genetic loss of Adm expression in the fetal 
placenta causes under-recruitment of uterine natural killer (uNK) cells and a loss of spiral 
artery remodeling, phenotypes consistent with the development of preeclampsia, a 
dangerous placenta-driven complication of pregnancy.59 Consistent with murine data, we 
previously found the biomarker mid-regional pro-adrenomedullin (MR-proADM) to be 
reduced in women with severe preeclampsia and a polymorphism within the human Adm 
gene to be associated with reduced birth weight, highlighting its relevance to human 
pregnancy.60,61 In summary, our findings provide molecular insights into the compartmental 
effects of AM signaling in the uterus during peri-implantation and highlight a potential 
therapeutic for poor implantation, possibly in the context of ART. Most importantly, studies 
addressing the safety and efficacy of intra-uterine delivery of AM in humans are merited and 







Figure 2-A1. Graphical abstract. AM, adrenomedullin; CLDN1, claudin 1; Cx43, connexin 
























Figure 2-1. AM improves implantation success and spacing in mice. A, Images of e6.5 
embryos within uteri treated with vehicle, AM, or AM + AM(24-50) prior to transfer of 8 
blastocysts per horn. Arrowheads indicate viable implantation sites as determined by uptake 
of Evans blue dye. Scale bar, 1 cm. B, Quantitation of viable implant sites per horn. Dots 
represent uterine horns. ns, not significant. *p<0.05, Mann-Whitney test. C, Illustration of 
quantitation method for spacing of e6.5 embryos within uterine horns. SD, standard deviation. 
D, Quantitation of spacing in vehicle- (n=26), AM- (n=21), and AM + AM(24-50) (n=25) horns 





Figure 2-2. Scanning electron micrographs of pinopodes and other ultrastructure 
features of uterine epithelial cells in wild type mice on day 2.5 of pseudopregnancy. A, 
Box encloses the image displayed in (B). Scale bar, 10 μm. B, Juxtaposition of a single large 
pinopode and many smaller pinopodes. Arrow points to a potentially degenerate pinopode. 
Scale bar, 5 μm. C, Pinopodes projecting above the epithelial cell layer into the lumen of the 
uterus. Scale bar, 1 μm. D, Arrows point to potentially degenerate pinopodes. Arrowheads 






Figure 2-3. AM promotes pinopode formation and size. A, Scanning electron micrographs 
of pinopodes in wild type uteri treated with vehicle, AM, or AM + AM(24-50) for 30 minutes. 
Scale bars, 5 μm. B-D, Quantitation of pinopodes per field (B), size (C), and percent area of 





Figure 2-4. AM accelerates pinopode formation dynamics in wild type mice between 
days 2.5-3.5 of pseudopregnancy. A, Scanning electron micrographs of vehicle- and AM-
treated uteri throughout treatment time course. Scale bars, 1 μm. B, Quantitation of pinopodes 
per field throughout treatment time course. n≥6 fields total from n=3 animals per treatment 
group. *p<0.05 at indicated time point, Bonferroni post-tests following two-way ANOVA, which 





Figure 2-5. AM enhances uterine wet:dry weight in vivo and water transport across 
Ishikawa cells in vitro. A, Wet:dry weight ratio of wild type uteri on day 2.5 of 
pseudopregnancy. n=3 animals per treatment group. *p<0.05, unpaired t test. B, Change in 
transepithelial resistance (TER) of Ishikawa cells seeded at densities of 100,000 and 250,000 
cells per transwell compared to a blank transwell between days 1 and 6 of culture. n≥3 cultures 
per time point. **p<0.01, ***p<0.001, Bonferroni post-tests at each density compared to blank 
after two-way ANOVA. C and D, Changes in short-circuit current (C) and TER (D) after 
addition of activators and inhibitors of ion channels following vehicle- and AM-pre-treated 
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cultures (n=3 per pre-treatment group). E, Representative image of calcein-loaded Ishikawa 
cells used in water permeability experiment. Rectangle encloses representative series of 
adjacent cells analyzed for changes in cell height and fluorescence after addition of hypertonic 
solution. Scale bar, 50 μm. F, Percent change in Ishikawa cell height after vehicle (n=5 
cumulative treatments from 3 cultures) and AM (n=6 cumulative treatments from 3 cultures) 
pre-treatment followed by hypertonic shock. Data is presented as mean + SEM (vehicle) or 
mean – SEM (AM). Slopes were calculated by linear regression analysis. ***p<0.001, 
ANCOVA. G, Percent change in calcein fluorescent intensity after hypertonic shock. Data is 
presented as mean – SEM (vehicle) or mean + SEM (AM). Slopes were calculated by linear 





Figure 2-6. AM contributes to proper CLDN1 localization. Immunohistochemistry for 
CLDN1 in wild type (n=3) and Adm+/- (n=4) e5.5 inter-implantation sites. Arrows denote 
CLDN1 localization, spanning the apical-basolateral axis of epithelial cell lateral borders 








Figure 2-7. AM enhances gap junction expression and communication in uterine 
stroma. A and B, Optical projection tomography (OPT) three-dimensional space filling scan 
(A) and Cx43 expression scan (B) of a wild type e5.0 implantation site and adjacent inter-
implantation sites. IB4 lectin staining indicates endothelium and embryonic tissue. Scale bars, 
400 μm. C, Immunohistochemistry for Cx43 in uteri treated with vehicle or AM for 30 minutes. 
Clusters of signal at the periphery of the AM image are autoflurescent red blood cells. n=3 
animals per treatment group. Scale bars, 100 μm. D, Bright field (top) and inverted fluorescent 
(bottom) images of a scrape loading assay in hESCs. Dotted lines indicate location of the 
scrape. E, Quantitation of distance traveled by lucifer yellow dye from the scrape. CBX, 
carbenoxolone, a gap junction inhibitor. n=3 fields per treatment group. ***p<0.001, unpaired 
t test. F, Quantitation of distance traveled by biotinylated BSA toward the embryo of e7.5 
Adm+/+ (n≥7 per axis) and Adm+/- (n≥25 per axis) implantation sites as a percentage of the 
total length of the axes depicted in (A). *p<0.05, unpaired t test. G, Representative images of 
e7.5 Adm+/+ and Adm+/- implantation sites stained for diaminobenzidine to assess the 
penetration of biotinylated BSA toward the embryo. The area within the dashed ellipses 
represents the zone not penetrated by BSA. Lines represent distance traveled by BSA toward 
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Objective: To test adrenomedullin (Adm, AM) as a downstream target of STAT3 in 
endometrial cells and to test mid-regional pro-adrenomedullin (MR-proADM) as a biomarker 
of endometriosis. 
Design: Cross-sectional analysis of adrenomedullin (Adm, AM) expression in eutopic 
endometrium and of MR-proADM in plasma from women with and without endometriosis. 
Prospective study of MR-proADM levels in women with endometriosis undergoing surgical 
resection of ectopic lesions. 
Setting: Academic medical centers in the United States. 
Patients: 15 patients with endometriosis and 11 healthy controls who donated eutopic 
endometrial biopsies; 28 patients with endometriosis and 19 healthy controls who donated 
plasma for MR-proADM analysis. 
Intervention(s): None. 
Main Outcome Measure(s): Adm mRNA levels by qRT-PCR after activation of STAT3 by IL-
6 in Ishikawa cells. Immunohistochemistry for AM in eutopic endometrial biopsies from 
women with endometriosis compared to healthy donors. MR-proADM levels measured by 
                                                
1Under Review: Matson BC, Quinn KE, Lessey BA, Young SL, & Caron KM. Mid-regional pro-
adrenomedullin is a potential biomarker of endometriosis. 
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commercial immunoassay in plasma from healthy women and women with endometriosis 
who subsequently underwent surgical resection of ectopic lesions. 
Result(s): Activation of STAT3 by IL-6 upregulated Adm mRNA expression in Ishikawa cells. 
AM protein levels were elevated in the eutopic endometrium of women with endometriosis. 
MR-proADM concentrations were higher in women with endometriosis but were not 
correlated with disease stage, corrected by surgery, or predictive of fertility outcome. 
 
Introduction 
Endometriosis is a common gynecological disease characterized by the presence of 
endometrial tissue outside of the eutopic endometrium, commonly in the peritoneum of the 
pelvis and in pelvic organs, often causing scarring and pain.1,2 Although endometriosis is 
also strongly associated with subfertility and infertility, the mechanisms underlying fertility 
problems in women with stage 1 to 2 disease is a subject of debate in the field.3,4 The non-
specific nature of endometriosis symptoms makes the disease difficult to diagnose, and 
confident diagnosis usually requires visualization of ectopic lesions at surgical exploration. 
Endometriosis is equally difficult to treat; hormonal therapies and surgical excision of ectopic 
lesions are the mainstays of treatment but are not always effective.5,6 These diagnostic and 
therapeutic challenges have fueled interest in identifying biomarkers and signaling pathways 
associated with endometriosis.7 
 Recently, Kim et al. demonstrated aberrant activation of signal transducer and 
activator of transcription 3 (STAT3) in the eutopic endometrium of women with 
endometriosis.8 Other studies consistently point to endometriosis-associated factors that 
affect STAT3 activation: the cytokine interleukin 6 (IL-6), which activates STAT3 through the 
IL-6 receptor, is elevated in the peritoneal fluid of women with endometriosis;9-11 miR120, 
which targets STAT3, is elevated in endometriotic cyst stromal cells;12 and protein inhibitor 
of activated STAT3 (PIAS3) and dual-specificity phosphatase-2 (DUSP2), negative 
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regulators of STAT3, are downregulated in endometriosis.13,14 Kim et al. also found hypoxia 
inducible factor 1A (HIF1A), which is stabilized by STAT3, to be elevated in the eutopic 
endometrium of women with endometriosis.8 Taken together, these data strongly implicate 
the IL-6-STAT3-HIF1A pathway in the pathophysiology of endometriosis. 
Both STAT3 and HIF1A have been previously identified as regulators of 
adrenomedullin (Adm, AM), a versatile peptide hormone.15-18 AM is expressed in the female 
reproductive system and has been associated with female reproductive physiology, 
including embryo implantation and placentation, and in pathophysiology, including 
subfertility and complications of pregnancy like preeclampsia.19,20 In endometriosis, AM has 
been found to be higher in intrafollicular fluid and negatively associated with oocyte maturity 
and embryo quality in women with endometriosis, underscoring a potential link between AM, 
endometriosis, and fertility.21 Collectively, these data imply that AM may be able to serve as 
a biomarker of endometriosis.  
 Mid-regional pro-adrenomedullin (MR-proADM) is a byproduct of post-translational 
processing of pre-pro-AM peptide and is a more stable analyte than the mature AM 
peptide.22 In the past decade, many groups have found prognostic value for MR-proADM 
plasma concentrations as a biomarker of heart failure,23 community-acquired pneumonia,24 
and sepsis,25 among other diseases. In reproduction, MR-proADM has been tested as a 
biomarker of gestational diabetes and preeclampsia.26,27 Here, we test the hypothesis that 
MR-proADM, as a surrogate for AM potentially downstream of the IL-6-STAT3 axis, can 
serve as a biomarker of endometriosis. 
 
Materials and Methods 
Study Design and Human Subjects 
 The study was approved by the Institutional Review Boards of Greenville Health 
System, Michigan State University, and the University of North Carolina at Chapel Hill. 
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Informed consent was obtained from all study participants, who were between the ages of 
18 and 45 and had not used hormonal therapies or an intrauterine device in the three 
months preceding biopsy or plasma collection. Eutopic endometrial biopsies were collected 
from healthy donor women and women with endometriosis in both proliferative and 
secretory phases at the time of surgery at Greenville Health System and the University of 
North Carolina. Plasma samples for analysis of MR-proADM concentrations were collected 
from healthy women and from women with endometriosis in both proliferative and secretory 
phases at Greenville Health System and the University of North Carolina. Patients who 
wished to conceive were followed expectantly after surgery for up to 6 months and 
pregnancies recorded. Pregnancy was defined as a visible gestational sac on ultrasound 
with cardiac activity and referral for obstetrical care. The clinical characteristics of women 
from whom plasma was collected is displayed in Table 3-1. MR-proADM concentrations 
were measured in undiluted plasma using a commercial assay (BRAHMS MR-proADM 
KRYPTOR) by Phadia Immunology Reference Laboratory. 
Immunohistochemistry 
 Five micron sections of paraffin-embedded endometrial biopsies were deparaffinized 
and hydrated. Following antigen retrieval in 10 mM citric acid/0.05% Tween 20, pH 6.0, 
endogenous peroxidase activity was quenched with 3% hydrogen peroxide in phosphate 
buffered saline (PBS). Tissues were permeabilized with PBS/0.1% Triton X-100 (PBST) and 
then blocked in 10% normal goat serum/1% bovine serum albumin in PBST. Tissues were 
incubated in anti-adrenomedullin primary antibody (1:200, Abcam ab69117) in block 
overnight at room temperature. The following day, slides were washed and incubated in 
biotinylated goat anti-rabbit (1:250, Jackson ImmunoResearch) for one hour. Avidin-biotin 
complexes (VECTASTAIN Elite ABC Kit, Vector Laboratories) were added to tissues for 30 
minutes, and then diaminobenzidine (DAB Peroxidase (HRP) Substrate Kit, Vector 
Laboratories) was added for two minutes. Slides were rinsed with tap water, counterstained 
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with hematoxylin (Vector Laboratories) for 20 seconds, and then rinsed with tap water again. 
Tissues were dehydrated and then coverslipped using DPX mountant (VWR). Slides were 
imaged on a Zeiss AxioImager with ProgRes CapturePro software (Jenoptik). Staining 
intensity was determined by a blinded observer (KEQ) and graded on a scale of 0 (no 
staining) to 4 (strong staining).  
Cell Culture, Western Blot, and qRT-PCR 
Ishikawa cells were cultured in DMEM/F12 (Gibco) + 10% fetal bovine serum (FBS) 
+ 1x penicillin/streptomycin (Gibco) in a 37°C incubator containing 5% CO2. For western blot 
analysis, Ishikawa cells were grown to confluency in 10 cm dishes and were treated with a 
vehicle control or 1, 10, or 100 ng/mL human IL-6 (R&D Systems) for 15 minutes. Cells were 
lysed in PBS + 10 nM NaF + 2 mM Na3(VO4) + 2mM PMSF + protease inhibitor cocktail, and 
protein concentration in the lysates was determined using a BCA Protein Assay Kit (Pierce).  
Twenty micrograms of protein per sample were loaded on a SDS-PAGE gel (Bio-Rad) and 
then transferred to a nitrocellulose membrane (GE Healthcare Life Sciences). Membranes 
were blocked in either 5% bovine serum albumin (Fisher Scientific) or 5% nonfat dry milk for 
one hour at room temperature and then incubated overnight at 4° in primary antibodies: 
phospho-STAT3 (1:2,000 in 5% BSA, Cell Signaling) or STAT3 (1:2,000 in 5% milk, Cell 
Signaling). Blots were washed three times in tris-buffered saline/0.1% Tween 20 and then 
incubated for two hours at room temperature in secondary antibodies: DyLight 680 goat anti-
mouse (1:15,000, Thermo Scientific) and DyLight 680 goat anti-rabbit (1:15,000 Thermo 
Scientific). Membranes were then imaged on an Odyssey CLx (LI-COR). 
For gene expression analysis, Ishikawa cells were grown to near confluency in 10 
cm dishes and then serum starved overnight in serum-free media. Cells were treated with 
100 ng/mL IL-6 (R&D Systems) for 1 hour. RNA was collected and isolated using TRIzol 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. Complementary DNA 
was synthesized from 2000 ng of DNase-treated RNA using M-MLV reverse transcriptase 
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(Invitrogen). Quantitative real-time PCR was performed using a human Adm Assay on 
Demand (Applied Biosystems, Hs00969450_g1) and human GAPDH primers and probe 
(Applied Biosystems, 4310884E) on a StepOne Plus (Applied Biosystems). qRT-PCR data 
was analyzed using the 2-ΔΔCt method. 
Statistical Analyses 
 All statistical analyses were performed in Prism 5 (GraphPad Software, Inc.). Adm 
gene expression in vehicle- and IL-6-treated Ishikawa cells was compared by unpaired t-test 
given the expected small effect size. AM staining intensity in endometrial compartments in 
biopsies from healthy women and women with endometriosis was compared by Mann-
Whitney test, as the data are not normally distributed. Composite AM staining scores and 
MR-proADM concentrations in plasma from healthy women and women with endometriosis 
were normally distributed and compared by unpaired t-test. MR-proADM concentrations by 
menstrual cycle phase; stage of disease; surgical status; and fertility outcome were 
compared by Kruskal-Wallis test. Data was considered statistically significant if p<0.05. 
 
Results 
Activation of STAT3 by IL-6 induces Adm expression 
 Given elevated levels of IL-6 and phosphorylated STAT3 (pSTAT3) in peritoneal fluid 
and eutopic endometrium, respectively, of women with endometriosis,9-11 and given prior 
evidence for STAT3 regulation of Adm expression,16,17 we tested whether IL-6 could induce 
Adm expression in an endometrial cell line, Ishikawa cells. First, we treated Ishikawa cells 
with increasing doses of IL-6 to confirm that IL-6 induced phosphorylation of STAT3 in 
Ishikawa cells. Indeed, we observed an IL-6 dose-dependent increase in pSTAT3 by 
western blot (Figure 3-1A). We then assessed whether IL-6-mediated phosphorylation of 
STAT3 induced Adm expression, finding that treating Ishikawa cells with 100 ng/mL IL-6 for 
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15 minutes upregulated Adm gene expression approximately 1.4-fold by qRT-PCR (Figure 
3-1B).  
AM staining is enhanced in eutopic endometrium of women with endometriosis 
 Considering the elevation of pSTAT3 in endometriotic endometrium coupled with our 
in vitro evidence for STAT3-mediated upregulation of Adm expression in endometrial cells, 
we asked whether AM is also upregulated in the endometrium of women with endometriosis. 
Indeed, we found that AM staining was significantly greater in luminal epithelium, glandular 
epithelium, and stroma of eutopic endometrium from women with endometriosis compared 
to healthy controls (Figure 3- 2).  
MR-proADM plasma levels are elevated in women with endometriosis 
 We then asked whether circulating plasma levels of MR-proADM, a stable precursor 
to the mature AM peptide, are elevated in women with endometriosis. The clinical 
characteristics of healthy controls and women with endometriosis who donated plasma for 
MR-proADM analysis are displayed in Table 3-1. First, we confirmed that MR-proADM levels 
are stable across all phases of the menstrual cycle in healthy women (Figure 3-3A). MR-
proADM levels averaged approximately 0.35 nmol/L, which is nearly equivalent to the mean 
MR-proADM concentration of 0.33 nmol/L across the general population.22 Subsequently, 
and consistent with higher levels of AM in eutopic endometrium of women with 
endometriosis, we found that circulating plasma levels of MR-proADM were higher in women 
with endometriosis compared to healthy controls (Figure 3-3B). However, MR-proADM 
levels did not vary by stage of disease (Figure 3-3C). 
 We then asked whether the elevated levels of MR-proADM were corrected by 
surgical resection of ectopic endometrial lesions. Analyzing MR-proADM concentrations 
immediately after surgery and three months after surgery, we determined that elevated MR-
proADM levels persisted through the post-surgical period (Figure 3-3D). Finally, we 
assessed whether MR-proADM concentrations before, after, and three months after surgery 
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correlated with whether participants were able to become pregnant. We did not find any 
difference in MR-proADM levels between women with endometriosis who became pregnant 
and those who did not (Figure 3-3E and F).  
 
Discussion  
 In this study, we have presented evidence for Adm as a potential STAT3 target in the 
uterus and investigated MR-proADM as a potential biomarker of endometriosis. Prior 
evidence for a STAT3-Adm axis is two-fold: first, pSTAT3 and Adm levels are positively 
correlated in breast cancer;16 and second, activation of STAT3 by oncostatin M promotes 
Adm transcription in astroglioma cells.17 However, to our knowledge, this is the first direct 
evidence for a STAT3-Adm axis in the uterus. This finding is not surprising, as pSTAT3 and 
AM are co-localized in the uterus during early pregnancy.28,29 Furthermore, reduction of 
STAT3 or AM in the uterus causes problems with endometrial receptivity and implantation, 
potentially due to defects in epithelial cell polarity, among other causes.28-31 It will be the 
subject of future studies to determine whether STAT3 causally upregulates Adm expression 
by directly binding active sites in the Adm promoter in uterine cells and if this interaction is 
critical for reproductive physiology and pathophysiology, specifically in the context of 
endometriosis. 
 We then asked whether AM, like pSTAT3, was upregulated in the eutopic 
endometrium of women with endometriosis, finding more AM in all epithelial and stromal 
compartments of the uterus. The increased expression is consistent with previously 
demonstrated elevated pSTAT3 and HIF1A abundance in the eutopic endometrium of 
women with endometriosis.8 However, the expression of AM in ectopic lesions remains 
unknown. 
 Because MR-proADM is a stable surrogate for AM peptide in circulating plasma, we 
compared levels of MR-proADM in women with and without endometriosis. This is the first 
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study, to our knowledge, to examine levels of MR-proADM across the menstrual cycle. As 
the MR-proADM assay was developed just over a decade ago, reference intervals in 
different physiological conditions and disease states are just emerging.32 Here, we 
contribute evidence for stable levels of MR-proADM across all stages of the menstrual cycle 
in healthy women. 
 Comparison of MR-proADM concentrations in women with and without endometriosis 
led to our primary finding of elevated MR-proADM in women with endometriosis. We posit 
several explanations for the finding: First, endometriosis is well-understood to be an 
estrogenic disease, and Adm is transcriptionally regulated by estrogen.33,34 Second, 
endometriosis is an inflammatory condition with consequences for fertility, and AM is an anti-
inflammatory peptide commonly upregulated in response to inflammation.35,36 Endometriosis 
is also associated with an elevated risk of epithelial ovarian cancer, and AM has been 
shown to promoter angiogenesis in this subtype of ovarian cancer.37-39 Therefore, our finding 
of elevated MR-proADM in women with endometriosis is consistent with associations 
common to both endometriosis and AM. 
 However, MR-proADM levels were not correlated with disease stage or corrected by 
surgical resection of ectopic lesions. Endometriosis staging determined primarily by the 
location and extent of ectopic lesions, and surgical resection aims to remove these lesions. 
Therefore, if ectopic lesions were the primary source of circulating MR-proADM, we would 
expect MR-proADM levels to be positively correlated with disease stage and to be corrected 
by surgery. While the expression of AM in ectopic lesions is not examined in this study, 
together, these data suggest that ectopic lesions are not the primary source of circulating 
MR-proADM. 
MR-proADM levels were not predictive of fertility outcome in women with 
endometriosis, which is associated with subfertility or infertility, in women who underwent 
surgery. However, studies by our group and others demonstrate that levels of both 
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maternal- and fetal-derived AM are important for fertility and pregnancy.19,20 It appears that 
AM levels are carefully titrated in normal physiology; for example, while Adm-/- mice are 
embryonic lethal, Admhi/hi mice, which overexpress AM, develop hyperplastic hearts during 
development.40,41 Therefore, it is becoming clear that concentrations of AM at either extreme 
can be detrimental to normal physiology. 
In summary, we present evidence for a potential STAT3-Adm interaction in the 
uterus; for upregulation of AM in the eutopic endometrium of women with endometriosis; 
and for higher circulating levels of MR-proADM in endometriosis. Whether elevated MR-
proADM in endometriosis is secondary to the estrogenic and inflammatory properties of 





  Control (n=19) Endometriosis (n=28) 
Age (years) 26.2 ± 4.4 (20-33) 32.9 ± 4.9 (23-41) 
BMI 22.4 ± 2.9 (18.3-28.2) 23.7 ± 4.7 (18.7-42.5) 
Gravidity at biopsy 0 (0-3) 0 (0-4) 
Race   
Caucasian 9 26 
African-American 7 0 
Asian 3 1 
Multiple 0 1 
Age and BMI are presented as mean ± standard deviation (range). Gravidity is presented as 
median (range). 
 







Figure 3-1. IL-6 activation of STAT3 upregulates Adm expression in Ishikawa cells. A, 
Western blot analysis of pSTAT3 expression in Ishikawa cells following a 15 minute treatment 
of varying doses of IL-6. n=1 biological replicate in Ishikawa cells, although the blot was also 
performed in primary human endometrial stromal cells as well as in a trophoblast cell line 
(HTR-8/SVneos) with nearly identical results. B, qRT-PCR analysis of Adm expression in 






Figure 3-2. Immunohistochemistry for AM in endometrial biopsies reveals elevated 
levels of AM in women with endometriosis. A, Representative images of 
immunohistochemistry for AM in eutopic endometrial biopsies from women with endometriosis 
and from healthy controls. GE, glandular epithelium; LE, luminal epithelium; S, stroma. B-D, 
Semi-quantitative analysis of AM staining in luminal epithelium (B), glandular epithelium (C), 
and stroma (D) of endometrial biopsies. DAB score reflects no (0), weak (1), moderate (2), or 
strong (3) staining. **p<0.01, Mann-Whitney test. E, Composite DAB score calculated as the 
sum of the compartmental DAB scores depicted in B-D. Luminal epithelium was not present 
in all endometrial biopsies from women with endometriosis, therefore LE DAB score and 
composite DAB score were unable to be calculated in all biopsies. Each dot represents an 






Figure 3-3. MR-proADM plasma concentrations are elevated in women with 
endometriosis but not correlated with disease stage, surgical status, or pregnancy 
outcome. A, MR-proADM concentrations in plasma from healthy women across all stages of 
the menstrual cycle. ns, not significant, Kruskal-Wallis. B, MR-proADM concentrations in 
healthy controls and women with endometriosis. **p<0.05, unpaired t-test. C, MR-proADM 
concentrations in women with endometriosis binned by disease stage and severity. ns, not 
59 
 
significant, Kruskal-Wallis test. D, MR-proADM concentrations in women with endometriosis 
before, immediately after, and three months after surgery. ns, not significant, Kruskal-Wallis 
test. E, MR-proADM concentrations in women with endometriosis pre-, post-, and three 
months post-surgery, binned by those who became pregnant and those who did not. ns, not 
significant, Kruskal-Wallis test. F, Individual, patient-level MR-proADM concentrations over 
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Chapter 4: Conclusions and Future Directions 
 
 
Summary of Results 
 Our basic science studies using genetic loss-of-function and pharmacologic gain-of-
function mouse models, presented in Chapter 2, demonstrate that administration of AM 
peptide directly into the uterus prior to blastocyst transfer improves implantation success 
and inter-embryonic spacing. Examination of the uterine luminal epithelium in this AM-
supplemented in vitro fertilization (IVF) model revealed morphological changes believed to 
be associated with endometrial receptivity and therefore fertility. Namely, we observed a 
greater number of pinopodes, plasma membrane extravasations of the epithelium projecting 
into the lumen of the uterus, which were bigger in size and covered a larger percentage of 
the epithelial surface compared to the pinopodes in vehicle-treated animals. As pinopodes 
have been associated with pinocytosis in rats, we then took advantage of a uterine luminal 
epithelial-like cell line to test whether AM affected movement of ions and water across the 
plasma membrane. We found that AM treatment improved plasma membrane permeability, 
accelerating water transport across the apical membrane unaccompanied by changes in ion 
transport. 
 We also examined changes in junctional proteins in the epithelial and stromal 
compartments of the uterus with varying dosages of AM peptide. Compared to wild type 
animals, female mice haploinsufficient for Adm demonstrated aberrant localization of 
CLDN1, a tight junction protein previously associated with fertility, in the uterine luminal 
epithelium. In stroma, we found that AM enhanced gap junction-mediated communication, 
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which could potentially explain the decreased functionality of the PDZ barrier observed in 
heterozygous animals. 
 These junctional phenotypes of loss- and gain-of-AM-function in vivo mouse models, 
together with a precedent for a STAT3-Adm interaction,1 prompted us to test whether AM 
might be a downstream target of STAT3. Indeed, our in vitro studies in Chapter 3 using 
Ishikawa cells, a uterine luminal epithelial-like cell line, demonstrate that activation of STAT3 
via IL-6 upregulates Adm mRNA expression. This data provides a first glimpse into a 
potential STAT3-Adm interaction in the uterus. 
 Finally, after demonstrating clear benefit for AM supplementation during implantation 
and establishing preliminary evidence for Adm as a downstream target of a signaling 
pathway essential for fertility, we turned to available clinical samples from women with 
endometriosis to ask whether AM levels were changed in a disease associated with 
infertility. First, we found elevated AM by immunohistochemistry in eutopic endometrial 
biopsies from women with endometriosis compared to biopsies from healthy donors. We 
then took advantage of a commercial assay for MR-proADM, a precursor of the mature AM 
peptide, as a circulating biomarker in plasma. Consistent with the biopsy data, we found 
higher circulating levels of MR-proADM in women with endometriosis. However, MR-
proADM concentrations were not correlated with disease stage nor corrected by surgery or 
predictive of pregnancy outcome. 
 
Future Directions 
At the Molecular Level – Regulation of AM Signaling in the Uterus 
 In Chapter 3, we suggest that activation of STAT3 by IL-6 upregulates Adm 
expression in uterine cells, implicating Adm as a downstream target of STAT3. We chose IL-
6 as an activator of STAT3 in our in vitro experiments because aberrant IL-6-STAT3 
signaling has been associated with endometriosis.2-5 However, in the future, we would be 
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remiss not to consider other activators of STAT3, of which there are many. It would be 
especially important to test LIF as an activator of STAT3, as the LIF-STAT3 axis is a key 
signaling pathway supporting endometrial receptivity and female fertility. Regardless of the 
ligand/receptor combination that activates STAT3 and leads to Adm upregulation, we would 
then begin our search for active STAT3 response elements (STREs) in the Adm promoter. 
One published study presents two different STREs in the Adm promoter, but details on the 
discovery of these two sites are lacking.1 Therefore, we could interrogate the Adm promoter 
for STAT3 binding motifs and then interrogate these potential STREs using luciferase 
assays and chromatin immunoprecipitation (ChIP). In the context of these assays, we could 
then interfere with STAT3 signaling by lentiviral or pharmacological knockdown of STAT3 or 
by generating point mutations in candidate STREs.  
 One caveat to our in vitro studies in Chapter 3 is the use of Ishikawa cells as a 
model for receptive uterine luminal epithelium. Ishikawa cells often generate skepticism 
because they were derived from an endometrial adenocarcinoma.6 However, commercially 
available cell lines that are better models of receptive epithelium do not exist.7 We would be 
better served by collecting primary epithelial cells from either mice or humans, but the 
collection and subsequent use of these cells in cell culture studies like luciferase assays and 
ChIP as discussed above are technically cumbersome. 
Given the dynamic environment of the uterus during early pregnancy and 
implantation, it would be worth considering whether the regulation of AM signaling is 
different in the epithelial and stromal compartments of the uterus. In contrast to primary 
epithelial cells, primary human endometrial stromal cells (hESCs) are available in our 
laboratory and easy to handle in cell culture. In vivo, we could take advantage of available 
Cre lines that delete in the epithelium (Ltf-iCre) and stroma (Amhr2-Cre) of the uterus.8,9 We 
could cross these Cre lines to the floxed STAT3 line to delete STAT3 in the epithelium and 
stroma and then to the Rpl22tm1.1Psam (RiboTag) line, enabling us to analyze compartment-
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specific mRNA based on which promoter is driving Cre expression.10 If STAT3 upregulates 
Adm expression, we would expect STAT3 excision by Cre recombinase to downregulate 
Adm mRNA. This may be true in one or both compartments of the uterus and may be 
different depending on the day of pregnancy studied. Ultimately, if we established STAT3 as 
a transcriptional activator of Adm, we would have identified an additional downstream target 
of STAT3 in the uterus and an additional regulator of Adm expression, third to estrogen and 
hypoxia via HIF1-α.11-13 
 
At the Cellular Level – Epithelial Cell Polarity and Ultrastructure 
 In Chapter 2, we begin to explore the role of cell junction proteins in the 
endometrium during implantation. In epithelium, we examined CLDN1, a tight junction 
protein, in the context of Adm haploinsufficiency. In stroma, we examined Cx43, a gap 
junction protein, in the context of exogenous AM supplementation. However, there are many 
other junctional proteins expressed in the epithelium and stroma. Several of these have 
been implicated in fertility as it is becoming clearer that loss of epithelial cell polarity is an 
important prerequisite for healthy embryo implantation.14,15 It would be important to study 
other junctional proteins in the epithelium and stroma throughout early pregnancy in Adm+/- 
animals as well as in wild type AM-treated animals. Examples of other junctional proteins we 
could study include additional claudins, E-cadherin, α-catenin, β-catenin, ZO-1, and ZO-2 
based on previously published studies on the expression of these proteins in the 
endometrium and in the early implantation site.16-18 
 Perhaps the most visually compelling images from our studies are the scanning 
electron micrographs of pinopodes presented in Chapter 2. Currently, scanning electron 
microscopy (SEM) is the best – and essentially the only – way to visualize pinopodes, 
limiting the questions that we are able to ask. Immunogold labeling in the context of SEM is 
possible and has been done by one group to study the expression of galectin-9 in 
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pinopodes.19 However, immunogold labeling cannot facilitate colocalization studies, as only 
one protein can be labeled at a time. Therefore, the application of imaging modalities other 
than SEM, such as whole mount immunofluorescence, to the study of pinopodes would be 
highly desirable and informative. Basic yet important questions about pinopodes that could 
be answered using confocal fluorescent microscopy include: Are they different than cell 
blebs found in other epithelial layers? What proteins are expressed on the surface of 
pinopodes? What proteins, if any, are expressed within these structures? 
 Once we answer these questions and identify reliable markers of pinopodes, we may 
be able to use these findings to help us establish an in vitro kinetic model to interrogate 
pinopode function. One group claims to have visualized pinopodes by SEM in an in vitro co-
culture system consisting of Ishikawa cells and hESCs.20 However, as discussed previously, 
the use of Ishikawa cells presents its own challenges, and co-culture of primary human 
luminal epithelial cells and hESCs may be a better alternative. Establishment of an in vitro 
system that generates pinopodes could then be used to determine pinopode function. The 
hypothesized pinocytotic function of these structures led to the term “pinopode.”  However, 
the few published studies on this pinocytotic function have come to different conclusions 
based on the species in question. For example, there is support for pinopode pinocytosis in 
rats but not in humans.21-24 Whether pinopodes demonstrate pinocytosis in the mouse is 
unknown. With an in vitro kinetic model in hand, we may be able to address this question. 
We could also investigate the interactions or lack thereof between pinopodes and the 
implanting blastocyst, as it is unknown whether pinopodes facilitate or obstruct initial contact 
of the blastocyst with the epithelium. 
 Both in vitro and in vivo studies on pinopodes are limited by the unavailability of a 
standard way to pharmacologically or genetically eliminate pinopodes. Several studies point 
to estradiol; RU486, a progesterone inhibitor; testosterone; and metoclopramide, a 
dopamine receptor antagonist, as pharmacological agents that decrease pinopode 
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expression.25-28 Therefore, we are presented with several avenues to pursue in the 
establishment of a negative control for our in vitro and in vivo studies on pinopodes. Of 
these three options, we are likely to prioritize RU486 given the positive correlation between 
serum progesterone concentration and pinopode expression in humans.29 If administration 
of RU486 to a pseudopregnant or pregnant mouse is able to eliminate pinopode expression, 
these animals could serve as negative controls for our planned whole mount 
immunofluorescence studies. 
 
At the Organ Level – Endometrial Physiology during Implantation 
 An especially interesting finding presented in Chapter 2 is that AM enhances the 
permeability of the Ishikawa cell apical membrane, leading to accelerated water transport. 
Water transport plays an important but underappreciated role in the endometrium, as it 
facilitates appropriate luminal fluid viscosity and closure of the lumen around the embryo at 
the time of implantation. There are many studies characterizing aquaporin expression in the 
endometrium but only one study linking aquaporins and AM: One study found a positive 
correlation between plasma AM levels and urinary aquaporin 2 levels in human patients 
under general anesthesia, but whether there is a link between aquaporins and AM in the 
endometrium is to be determined.30 
 Similarly, there is a sizeable body of literature on ion channels, including cystic 
fibrosis transmembrane conductance regulator (CFTR), epithelial sodium channel (ENaC), 
Ca2+ channels, and K+ channels and their importance in endometrial receptivity and 
implantation.31 In our Ussing chamber studies presented in Chapter 2, we did not find 
changes in Ishikawa cell short-circuit current or transepithelial resistance after addition of a 
series of ion channel modulators following AM pre-treatment. However, these studies were 
performed in Ishikawa cells, so we could consider repeating these studies in primary human 
endometrial epithelial cells. In vivo, we could interrogate links between AM and aquaporins 
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and ion channels by assessing luminal fluid content as well as aquaporin and ion channel 
mRNA expression in several different mouse models: 1) our AM-supplemented blastocyst 
transfer model; 2) our Adm haploinsufficient model of subfertility; and/or 3) deletion of the 
AM receptor and therefore AM signaling using endometrial compartment-specific Cre lines. 
 Another piece of data presented in Chapter 2 that supports a link between AM and 
aquaporins and ion channels is the finding that administration of AM prior to blastocyst 
transfer equalized spacing between embryos at e6.5. While embryo spacing in the uterus is 
incompletely understood, there are many hypothesized determinants of spacing – including 
water and ion channels function and consequent changes in luminal fluid.32 One potentially 
high-yield experiment would be to perform our AM-supplemented blastocyst transfer 
protocol in Ltf-iCre;Rpl22tm1.1Psam (RiboTag) pseudopregnant recipients and then perform a 
microarray on RiboTag-tagged mRNA, which would be specific to luminal epithelium. It is 
possible that this experiment would identify changes in aquaporins and/or ion channels with 
AM treatment – or other, unexpected pathways – that could explain the enhanced 
implantation rate and equalized spacing between embryos. 
 
At the Organism Level – Rescue of Alternative Models of Subfertility and Infertility 
 Our primary finding of enhanced implantation success after pre-implantation 
administration of AM was obtained in wild type CD1 mice. It would be interesting to test 
whether we could rescue our Adm haploinsufficient mouse model of subfertility with AM. We 
could also perform our AM-supplemented blastocyst transfer protocol in wild type mice of 
another strain with below average fertility – in either commercially available strains or 
several strains from UNC’s Collaborative Cross. Alternatively, we could antagonize 
endometrial receptivity pharmacologically and then attempt to rescue with AM. For example, 
systemic morphine administration has been shown to interfere with endometrial receptivity.33 
We attempted to co-treat with complement factor H (CFH), the binding partner of circulating 
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AM peptide, in order to bolster the AM effect but surprisingly found that co-treatment with 
CFH was antagonistic to implantation. A couple of hemodynamic studies have found that co-
treatment with a neural endopeptidase inhibitor enhances the efficacy of AM, so we could 
also considering incorporating this treatment scheme into our blastocyst transfer 
protocol.34,35 
 Finally, we could look beyond the peri-implantation period at mid-gestation and early 
postnatal development to ensure that embryos are not adversely affected by the pre-
implantation administration of AM. For example, we could compare litter sizes between 
vehicle- and AM-treated animals at e13.5 and at birth and embryo and placenta weights at 
each of these time points. One potential concern is embryonic cardiac hyperplasia as 
demonstrated by Admhi/hi embryos.36 However, these embryos are constitutively exposed to 
high levels of AM, whereas the embryos in our blastocyst transfer model are only transiently 
exposed. These studies would be especially important to perform before clinical usage of 
AM in the context of assisted reproductive technology becomes a possibility. 
 
In the Clinic – AM as Therapeutic for Infertility 
 Ultimately, we believe that administration of AM directly into the uterus could improve 
the clinical pregnancy rate following assisted reproductive technology like intrauterine 
insemination (IUI) or IVF. To this end, first-pass experiments in the clinic could address the 
safety of AM treatment in humans. For example, we could infuse AM directly into the uterus 
for a short time while monitoring patients for safety, paying particular attention to any 
hemodynamic abnormalities. Because the delivery of AM – a potent vasodilator – is 
localized and not systemic, we are optimistic that this delivery route would avoid 
hypotensive episodes. We could then obtain endometrial biopsies for analysis of pinopodes 
by SEM in an attempt to recapitulate our mouse findings in humans. The correlation 
between pinopode expression and endometrial receptivity is debated, as both Lif-/- and 
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Hoxa10-/- mice are infertile but have pinopodes,37 but a clinical study just published this year 
maintains a link between pinopodes and fertility.38 
 In the past several years, an endometrial receptivity array (ERA) has been 
developed to characterize the gene signature of the receptive endometrium and to assist 
with the diagnosis of endometrial-factor infertility.39,40 Therefore, it would be interesting to 
collect RNA from endometrial biopsies and compare ERA outputs between vehicle- and AM-
infused uteri, which we could then compare to the effects of endometrial scratching and G-
CSF administration, both of which have been shown to enhance clinical pregnancy rates in 
assisted reproductive technology.41,42 
 Finally, we examined MR-proADM as a biomarker of endometriosis, which is a co-
morbid with subfertility and infertility, finding elevated levels of MR-proADM in plasma from 
women with endometriosis compared to healthy controls. Whether this elevation is because 
AM is involved in the pathophysiology of endometriosis or secondary to the estrogenic and 
inflammatory environment of endometriosis is unknown. If we wish to pursue AM as a 
therapy for infertility, perhaps it would be better to analyze MR-proADM concentrations in 
women with endometrial-factor infertility and recurrent implantation failure (RIF). Based on 
our studies on AM and female fertility in mice, we would predict that women with RIF would 
have lower levels of MR-proADM than healthy women. Women with RIF and low MR-
proADM would then represent a germane patient population in which we could pilot AM 
therapy to improve clinical pregnancy and live birth rates following IUI and IVF. 
 
Concluding Remarks 
 In Part I, we have followed up on the Caron laboratory’s Adm haploinsufficiency and 
subfertility studies from a decade ago.43,44 Specifically, we highlight potential mechanisms of 
action of AM in the epithelial and stromal compartments of the endometrium supporting 
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implantation and early pregnancy. We also conclude that administration of AM directly into 
the uterus prior to blastocyst transfer improves embryo implantation success, providing a 
foundational basis for using AM as a clinical therapy for infertility, likely in combination with 
assisted reproductive technology like IUI and IVF. The stage is set for many experiments in 
both the laboratory and the clinic that will inform our efforts to use AM to enhance the live 
birth rates following these procedures. Finally, based on our MR-proADM biomarker studies, 
we also suggest that AM may be involved in the pathophysiology of endometriosis, a 
disease associated with subfertility and infertility, though further study is necessary to 
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PART II – MAINTENANCE OF PREGNANCY 
 
 





 Precise and local control of the innate immune system within the placenta is an 
essential component for achieving a normal and healthy pregnancy. One of the most 
abundant immune cells of the placenta is a subpopulation of natural killer (NK) cells that 
profusely populates the uterine decidua during early pregnancy. Uterine NK (uNK) cells and 
trophoblast cells of the placenta communicate both directly and indirectly to contribute to the 
critical process of spiral artery remodeling. Here, we discuss recent findings that expand our 
knowledge of uNK cell-trophoblast cell crosstalk and the important role it plays in the 
maternal vascular adaptation to pregnancy. 
 
Introduction 
 Natural killer (NK) cells are lymphocytes belonging to the innate immune system that 
attack virally-infected cells and tumor cells via exocytosis of perforin- and granzyme-
containing granules. In females, there are two populations of NK cells: peripheral blood (pb) 
NK cells and decidual (d) or uterine (u) NK cells. Both NK cell populations are capable of 
                                                
1Reprinted with permission from: Matson BC & Caron KM. Uterine natural killer cells as modulators of 
the maternal-fetal vasculature. Int J Dev Biol. 2014;58:199-204. 
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cytotoxicity and cytokine secretion. However, pbNK cells are primarily lytic cells, while uNK 
cells are primarily cytokine and chemokine producers. 
 A dramatic expansion of uNK cells occurs during early pregnancy, populating two 
adjacent areas of the implantation site, the decidua basalis (DB) and the mesometrial 
lymphoid aggregate of pregnancy (MLAp). Proliferation continues until mid-pregnancy, at 
which point uNK cells comprise up to 70% of immune cells present in the decidua, the 
progesterone-altered endometrium of the uterus that supports the conceptus.1 uNK cell 
population size then declines until the end of pregnancy. 
 Molecular characterization of uNK cells has led to the identification of subpopulations 
of uNK cells in the decidua. Mouse uNK cells, previously identified by periodic acid Schiff 
(PAS) staining, are also currently identified by Dolichos biflorus agglutinin (DBA) lectin 
staining.2 PAS and DBA lectin staining defines two subpopulations of uNK cells: PAS+DBA- 
and PAS+DBA+ cells, which exhibit different gene expression profiles.3,4 While PAS is a pan-
uNK cell marker, DBA lectin detects the subpopulation of cells that expands during 
pregnancy, as 90% of uNK cells at mid-gestation are DBA+.4 
In contrast to the mouse, human uNK cells are identified by their CD56 CD16 
signature. The vast majority of uNK cells are CD56brightCD16-, and pbNK cells are typically 
CD56dimCD16+. Interestingly, while both subpopulations are present in the decidua, the 
proportion of these two subsets can shift to favor cytotoxic CD56dimCD16+ cells in the 
presence of infectious agents like cytomegalovirus5 and Toxoplasma gondii,6 both common 
intrauterine infections that cause severe birth defects. 
 Despite belonging to the immune system, the primary contributions of uNK cells to 
the developing pregnancy are not immune in nature. Rather, uNK cell-secreted cytokines 
and chemokines communicate with fetal trophoblast cells of the placenta.7 These two cell 
types act in concert to remodel spiral arteries, conduits of blood from the uterus to the 
placental bed and growing fetus.8 The importance of this process is stressed by the 
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association of insufficient spiral artery remodeling with several diseases of pregnancy, such 
as fetal growth restriction (FGR) and preeclampsia. Here, we briefly review aspects of uNK 
cell-trophoblast cell crosstalk and their role in spiral artery remodeling and the maintenance 
of pregnancy. 
 
uNK Cell Differentiation 
 Little is known about uNK cell precursors and the source of the expanded uNK cell 
population during pregnancy. However, there is evidence to suggest that the majority of uNK 
cell precursors originate from outside the uterus. In the early 2000s, Croy and colleagues 
were unable to detect differentiated uNK cells in NK cell-deficient animals engrafted with 
parts of wild type uteri, suggesting that uNK cell precursors are extra-uterine.9 More 
recently, analysis of changes in uNK cell surface markers during pregnancy suggest that 
uNK cells endogenous to the uterus decline between gestation day (gd) 0 and gd6, perhaps 
because their cytotoxicity would be lethal to the foreign conceptus.10 Therefore, the 
endogenous uNK cell population may be less critical for the maintenance of pregnancy than 
uNK cells that differentiated from extra-uterine precursors. 
 Macrophage-derived interleukin-15 (IL-15) is a critical regulator of NK and uNK cell 
differentiation. It was first observed that the time course of IL-15 expression during 
pregnancy parallels that of uNK cell granule contents.11 Soon thereafter, IL-15-/- animals 
were generated.12 IL-15-/- females lack uNK cells, MLAps, and spiral artery remodeling 
despite birthing litters of average size but slightly below-average weight.13,14 Recent 
microarray analysis comparing IL-15-/- and wild type animals did not detect differences in 
expression levels of genes involved in decidualization.15 Therefore, the finding of below-
average weight pups born to IL-15-/- dams cannot be explained by differences in 
decidualization and is likely due to the effect of IL-15 on uteroplacental circulation via 
stimulation of uNK cell differentiation. 
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 Recent studies offer candidate regulators of IL-15 expression. For example, there is 
evidence that the transcription factor RUNX3 acts together with other transcription factors to 
promote IL-15 expression.16 However, there are also potentially indirect regulators of IL-15 
expression. For example, a conditional knockout (cKO) of bone morphogenic protein 
receptor 2 (Bmpr2) in the female reproductive system demonstrated decreased IL-15 
expression.17 As may be expected, Bmpr2 cKOs lacked uNK cells at implantation sites and 
exhibited defects in placentation. 
In another animal model of placental underperfusion, heme oxygenase-1 (HO-1) 
heterozygotes and knockouts also downregulated IL-15 expression and exhibited fewer uNK 
cells in the DB and MLAp.18 Similar to Bmpr2 cKOs, Hmox1+/- dams demonstrated 
intrauterine growth restriction (IUGR), suggesting poor uteroplacental circulation. 
Interestingly, treatment with CO, a byproduct of HO-1’s heme metabolism, elevated uNK cell 
numbers, promoted spiral artery remodeling, and decreased the incidence of fetal death. 
However, CO treatment did not elevate IL-15 levels. In an attempt to explain why IL-15 is 
downregulated in Hmox1+/- and Hmox1-/- animals, the authors suggest that CO may affect 
the activity of macrophages, a demonstrated source of IL-15 in the pregnant uterus.11 If true, 
this hypothesis could address the well-established, counterintuitive protection that smoking 
confers against preeclampsia. Altogether, these observations suggest potential indirect 
mechanisms of uNK cell differentiation via regulation of IL-15 expression. 
 
uNK-Trophoblast Cell Interactions: KIRs and HLAs 
 Differentiated uNK cells express activating and inhibitory cell surface receptors. 
Stimulation of these subtypes by trophoblast-expressed ligands, for example, determines 
the degree of uNK cell activity. Interestingly, the proportions of activating and inhibitory 
receptors may shift in the presence of a foreign pathogen to modify uNK cell activity and 
promote cytotoxicity.19 Many of these uNK cell surface receptors belong to the killer cell Ig-
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like receptor (KIR) family. KIR A and B haplotypes preferentially express inhibitory and 
activating receptors, respectively, and bind to fetal trophoblast-expressed human leukocyte 
antigen C (HLA-C), a major histocompatibility complex (MHC) type I molecule. 
Importantly, Moffett and colleagues demonstrated associations of certain KIR-HLA 
combinations – specifically KIR AA and HLA-C2 – with diseases of pregnancy like 
preeclampsia and miscarriage.20,21 Binding of fetal HLA-C2 to the inhibitory receptor 
KIR2DL1 in these women may predispose to preeclampsia and other placental disorders via 
insufficient uNK cell activation. In contrast, KIR B women preferentially express uNK cell 
activating receptors. In these women, HLA-C2 likely binds to the activating receptor 
KIR2DS1, protecting women against these diseases by activating uNK cells and stimulating 
trophoblast invasion.20,22 Recent evidence that KIR2DS1 stimulates secretion of cytokines 
like granulocyte macrophage colony-stimulating factor (GM-CSF) by uNK cells and 
trophoblast migration supports this paradigm.23  
While HLA-C has attracted attention for its disease associations, trophoblast cells 
express HLAs other than HLA-C. Specifically, they also express HLA-E and HLA-G. HLA-E 
binds to CD94/NKG2A, an inhibitory receptor on uNK cells,24 and HLA-G binds to leukocyte 
immunoglobulin-like receptors (LILRs) on uNK cells.25 However, HLA-G also binds to a KIR 
– CD158d/KIR2DL4, which is expressed in endosomes, not on the uNK cell surface like 
other KIRs.26 Binding of HLA-G to KIR2DL4 activates downstream pathways that confer a 
senescent phenotype on the uNK cell.27 Supernatants from KIR2DL4-stimulated uNK cells 
enhance the permeability and angiogenic capacity of human ubilical vein endothelial cells 
(HUVECs). It is easy, therefore, to imagine a role for uNK cells in placental vascular 
remodeling via HLA-G stimulation of KIR2DL4. 
Despite the attention paid to the consequences of HLA-KIR interactions, there is 
likely a role for non-KIR uNK cell receptors that bind to non-HLA ligands. Specifically, the 
aryl hydrocarbon receptor (Ahr) is expressed by DBA- uNK cells and may be important for 
83 
 
the proliferation of this oft-ignored uNK cell subset.28 While Ahr-/- implantation sites 
demonstrated wild type levels of total uNK cells, DBA+ cells were smaller, and DBA- cells 
were fewer in number.28 Ahr-/- animals also demonstrated insufficient spiral artery 
remodeling. Similarly, loss of natural cytotoxicity receptors (NCR), expressed by DBA+ cells, 
didn’t affect total uNK cell numbers but impaired uNK cell maturation and spiral artery 
remodeling.28 While the ligands for these receptors are unknown, they are clearly playing an 
important role in uNK cell maturation and activity, highlighting the importance of interactions 
outside the KIR-HLA axis. 
 
uNK Cell Recruitment by Trophoblast-derived Factors 
 uNK cell-trophoblast cell crosstalk extends beyond contacts between cell surface 
proteins. For example, trophoblast-derived peptides of the calcitonin (CT)/calcitonin gene-
related peptide (CGRP) family are involved in maintaining proper placental perfusion, 
possibly by communicating with uNK cells. The clearest link between a CGRP family 
member, uNK cells, and spiral artery remodeling is adrenomedullin (AM). 
 Levels of AM, an anti-inflammatory vasodilator, are physiologically elevated in 
normal pregnancy29 but altered in adverse pregnancy outcomes.30 Polymorphisms in the AM 
gene are associated with birth weight, glycemic regulation, and preeclampsia.31 AM localizes 
to implantation sites and is expressed by the uterine epithelium and fetal trophoblast cells.32 
Fetal trophoblast cells also express the AM receptor, calcitonin receptor-like receptor 
(CLR).33 Interestingly, Adm+/- females are less fertile due to diminished endometrial 
receptivity,34 and pups born to Adm+/- females are more likely to demonstrate FGR.32 
Altogether, these data suggest a role for maternal AM in implantation and placentation. 
 However, Adm-/- embryos are more likely to exhibit FGR than Adm+/- or Adm+/+ 
embryos, suggesting a role for fetal-derived AM in placentation. Adm-/- placentas 
demonstrate fewer uNK cells and retention of vascular smooth muscle cells lining spiral 
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arteries compared to Adm+/+ placentas.35 Concordantly, placentas from Admhi/hi pregnant 
females, a gene-targeted animal model of AM overexpression, exhibit 30% more uNK cells 
than AM+/+ placentas and upregulate cytokine, chemokine, and matrix metalloproteinase 
(MMP) expression. In vitro, uNK cell-conditioned media supplemented with AM promotes 
apoptosis of vascular smooth muscle cells, supporting the emerging role for uNK cells in 
spiral artery remodeling.35 It remains to be seen whether AM-mediated uNK cell recruitment 
and activity is dosage-dependent. 
Like AM, adrenomedullin 2 (AM2), also known as intermedin, is physiologically 
elevated during pregnancy.36 Administration of an AM2 antagonist causes FGR, highlighting 
the importance of AM2 in a healthy pregnancy.37 AM2 is expressed by trophoblast cells and 
stimulates their invasion via the mitogen-activated protein kinase (MAPK) signaling 
pathway.38,39 AM2 also dose-dependently stimulates HLA-G expression in trophoblasts cells, 
possibly stimulating KIR2DL4 signaling on uNK cells that could then acquire a senescent 
phenotype and increase vascular permeability and angiogenesis.27,38 It is appealing to test 
whether AM2 dosage correlates with uNK cell recruitment to the decidua and consequent 
spiral artery remodeling.  
Other CGRP family members also appear to modulate the uteroplacental circulation. 
For example, CGRP affects blood pressure regulation at the maternal-fetal interface, and its 
levels are altered in pregnancy-induced hypertension and preeclampsia.40-44 However, 
CGRP’s effects on uNK cell recruitment and activity remain to be elucidated.  
As may be expected, there are trophoblast-derived factors outside the CGRP family 
that communicate with uNK cells. For example, thrombopoietin (TPO) and its receptor, c-
Mpl, are expressed by uNK cells and trophoblast cells and act in concert to stimulate the 
proliferation and migration of these cell types via the JAK/STAT pathway.45 As we come to 
understand more about uNK cell-trophoblast cell crosstalk, we imagine that other 
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trophoblast-derived factors will come to light as important effectors of uNK cell recruitment 
and activation. 
 
Placental Vascular Remodeling by uNK Cell-derived Factors 
 uNK cells generate an array of angiogenic growth factors, cytokines, and 
chemokines in different proportions at different times of pregnancy, suggesting a continuous 
and evolving role for uNK cells as pregnancy progresses. Here, we briefly discuss several 
examples of uNK cell-derived factors, acknowledging that there are many others we do not 
address. 
Angiopoietin (Ang) 1 and 2, transforming growth factor β (TGF-β), and vascular 
endothelial growth factor (VEGF) are several examples of uNK cell-secreted angiogenic 
factors.46 Placental growth factor (PlGF) belongs to the VEGF family and has emerged as a 
potential biomarker for preeclampsia, emphasizing the significance of these angiogenic 
factors in proper uteroplacental circulation.47,48 VEGF-C also belongs to the VEGF family 
and may assume an additional role – protecting trophoblast cells from uNK cell 
cytotoxicity.49 The concentration of these factors decreases in the decidua as pregnancy 
progresses, suggesting that they may be irrelevant after spiral artery remodeling 
concludes.46 
 Interferon-gamma (IFN-γ) is a uNK cell-secreted cytokine that has arguably attracted 
the most attention in the literature; it is necessary and sufficient for spiral artery 
remodeling.50 IFN-γ inhibits trophoblast invasion by promoting apoptosis of trophoblast cells 
and altering protease levels, keeping trophoblast invasion in check.46 Perhaps 
counterintuitively, uNK cells from women with preeclampsia secrete less IFN-γ than uNK 
cells from normotensive controls.51 
 uNK cells also produce a variety of chemokines, including interleukin-8 (IL-8) and 
interferon-inducible protein-10 (IP-10). Receptors for these two chemokines, CXCR1 and 
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CXCR3, respectively, are expressed on the trophoblast cell surface, substantiating uNK 
cells’ candidacy as potent regulators of trophoblast invasion.7 However, IL-8 and IP-10 
presence in uNK cell-conditioned media (CM) isn’t different between pregnancies with 
normal and high uterine artery Doppler resistance indices.52 To generate uNK cell CM, the 
authors plated equal densities of uNK cells from the different pregnancies, which could 
explain this finding. uNK cell chemokine secretion could very well be equivalent cell to cell, 
but the two types of pregnancies may have different population sizes of uNK cells. CM from 
these pregnancies did differ in extracellular signal-regulated kinase (ERK) and Akt pathway 
activation, which are critical for trophoblast invasion. Therefore, it is possible that uNK cells 
of these two types of pregnancies differentially express chemokines other than the ones 
examined in this study. 
 Finally, uNK cells are also sources of MMPs such as MMP-2.53The previously 
mentioned peptide hormone AM stimulates MMP-9 secretion from uNK cells, triggering 
spiral artery smooth muscle cell apoptosis.35 Altogether, this orchestra of signaling 
molecules coordinates the complex process of spiral artery remodeling to maintain a healthy 
pregnancy. Intriguingly, angiogenic growth factors and cytokines decrease in concentration 
when uNK cells and trophoblast cells are co-cultured, though the cell type from which these 
factors are derived in this co-culture is uncertain.54 No doubt additional signals will be 
identified that will further our understanding of uNK cell-trophoblast interactions. 
 
Concluding Remarks 
 In summary, the overall immune milieu of the placenta is an important determinant of 
the health and success of a pregnancy.55,56 Perturbations in this complex environment by 
lipopolysaccharide-induced inflammation, for example, can cause abnormal placental 
vascular remodeling and phenotypes resembling FGR and preeclampsia.57 uNK cells 
dominate this immune landscape during early pregnancy and are important modulators of 
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the maternal-fetal vasculature. Generalized inflammatory changes triggered by obesity, for 
example, can cause under-recruitment of uNK cells to the decidua, which could explain why 
obesity elevates a patient’s risk of pregnancy complications.58 
 Certainly, there are other determinants of uNK cell density in the decidua during 
early pregnancy not discussed here, such as decidual cell-derived cytokines.59 However, it is 
likely that there are important effectors of spiral artery remodeling other than uNK cells;60 
several studies suggest that uNK cells may be important only during a small time frame of 
this process. Ultimately, furthering our understanding of uNK-trophoblast cell interactions 
and their role in placental vascular remodeling will shed light on placentation disorders like 







Figure 5-1. A combination of direct and indirect interactions between uterine natural 





1. Bulmer JN, Williams PJ & Lash GE. Immune cells in the placental bed. Int J Dev Biol. 
2010;54:281-294. 
2. Paffaro VA, Jr., Bizinotto MC, Joazeiro PP & Yamada AT. Subset classification of 
mouse uterine natural killer cells by DBA lectin reactivity. Placenta. 2003;24:479-488. 
3. Chen Z, Zhang J, Hatta K, Lima PD, Yadi H, Colucci F, Yamada AT & Croy BA. 
DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased 
gene expression. Biol Reprod. 2012;87:81. 
4. Zhang J, Chen Z, Smith GN & Croy BA. Natural killer cell-triggered vascular 
transformation: maternal care before birth? Cell Mol Immunol. 2011;8:1-11. 
5. Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, Bouteiller P & Jabrane-
Ferrat N. Human cytomegalovirus infection elicits new decidual natural killer cell 
effector functions. PLoS Pathog. 2013;9:e1003257. 
6. Xu X, Fu Q, Zhang Q, Zhao M, Gao Z, Liu X, Liu Y & Hu X. Changes of human 
decidual natural killer cells cocultured with YFP-Toxoplasma gondii: implications for 
abnormal pregnancy. Fertil Steril. 2013;99:427-432. 
7. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, 
Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, 
Porgador A, Keshet E, Yagel S & Mandelboim O. Decidual NK cells regulate key 
developmental processes at the human fetal-maternal interface. Nat Med. 
2006;12:1065-1074. 
8. Smith SD, Dunk CE, Aplin JD, Harris LK & Jones RL. Evidence for immune cell 
involvement in decidual spiral arteriole remodeling in early human pregnancy. Am J 
Pathol. 2009;174:1959-1971. 
9. Chantakru S, Miller C, Roach LE, Kuziel WA, Maeda N, Wang WC, Evans SS & Croy 
BA. Contributions from self-renewal and trafficking to the uterine NK cell population 
of early pregnancy. J Immunol. 2002;168:22-28. 
10. Takashima A, Ishikawa F, Kuwabara T, Tanaka Y, Kinoshita T, Ito M & Kakiuchi T. 
Uterine natural killer cells severely decrease in number at gestation day 6 in mice. 
Biol Reprod. 2013;89:101. 
11. Ye W, Zheng LM, Young JD & Liu CC. The involvement of interleukin (IL)-15 in 
regulating the differentiation of granulated metrial gland cells in mouse pregnant 
uterus. J Exp Med. 1996;184:2405-2410. 
12. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, 
Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, 
Joyce S & Peschon JJ. Reversible defects in natural killer and memory CD8 T cell 
lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780. 
90 
 
13. Ashkar AA, Black GP, Wei Q, He H, Liang L, Head JR & Croy BA. Assessment of 
requirements for IL-15 and IFN regulatory factors in uterine NK cell differentiation 
and function during pregnancy. J Immunol. 2003;171:2937-2944. 
14. Barber EM & Pollard JW. The uterine NK cell population requires IL-15 but these 
cells are not required for pregnancy nor the resolution of a Listeria monocytogenes 
infection. J Immunol. 2003;171:37-46. 
15. Bany BM, Scott CA & Eckstrum KS. Analysis of uterine gene expression in 
interleukin-15 knockout mice reveals uterine natural killer cells do not play a major 
role in decidualization and associated angiogenesis. Reproduction. 2012;143:359-
375. 
16. Levanon D, Negreanu V, Lotem J, Bone KR, Brenner O, Leshkowitz D & Groner Y. 
Runx3 Regulates Interleukin-15 Dependent Natural Killer Cell Activation. Mol Cell 
Biol. 2014; 
17. Nagashima T, Li Q, Clementi C, Lydon JP, DeMayo FJ & Matzuk MM. BMPR2 is 
required for postimplantation uterine function and pregnancy maintenance. J Clin 
Invest. 2013;123:2539-2550. 
18. Linzke N, Schumacher A, Woidacki K, Croy BA & Zenclussen AC. Carbon Monoxide 
Promotes Proliferation of Uterine Natural Killer Cells and Remodeling of Spiral 
Arteries in Pregnant Hypertensive Heme Oxygenase-1 Mutant Mice. Hypertension. 
2013; 
19. Xu X, Zhao M, Liu X, Jiang Y, Zhang H, Zhai X, Zhang L & Hu X. Toxoplasma gondii 
infection regulates the balance of activating and inhibitory receptors on decidual 
natural killer cells. PLoS One. 2013;8:e55432. 
20. Hiby SE, Walker JJ, O'Shaughnessy K M, Redman CW, Carrington M, Trowsdale J 
& Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk 
of preeclampsia and reproductive success. J Exp Med. 2004;200:957-965. 
21. Hiby SE, Regan L, Lo W, Farrell L, Carrington M & Moffett A. Association of maternal 
killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with 
recurrent miscarriage. Human Reproduction. 2008;23:972-976. 
22. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH, Walker 
JJ, Redman CW, Morgan L, Tower C, Regan L, Moore GE, Carrington M & Moffett 
A. Maternal activating KIRs protect against human reproductive failure mediated by 
fetal HLA-C2. J Clin Invest. 2010;120:4102-4110. 
23. Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, Bauer J, Hiby 
SE, Colucci F & Moffett A. Maternal uterine NK cell-activating receptor KIR2DS1 
enhances placentation. J Clin Invest. 2013;123:4264-4272. 
24. King A, Allan DS, Bowen M, Powis SJ, Joseph S, Verma S, Hiby SE, McMichael AJ, 
Loke YW & Braud VM. HLA-E is expressed on trophoblast and interacts with 
CD94/NKG2 receptors on decidual NK cells. Eur J Immunol. 2000;30:1623-1631. 
91 
 
25. Apps R, Gardner L, Sharkey AM, Holmes N & Moffett A. A homodimeric complex of 
HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. 
Eur J Immunol. 2007;37:1924-1937. 
26. Rajagopalan S. Endosomal signaling and a novel pathway defined by the natural 
killer receptor KIR2DL4 (CD158d). Traffic. 2010;11:1381-1390. 
27. Rajagopalan S & Long EO. Cellular senescence induced by CD158d reprograms 
natural killer cells to promote vascular remodeling. Proc Natl Acad Sci U S A. 
2012;109:20596-20601. 
28. Felker AM, Chen Z, Foster WG & Croy BA. Receptors for non-MHC ligands 
contribute to uterine natural killer cell activation during pregnancy in mice. Placenta. 
2013;34:757-764. 
29. Gibbons C, Dackor R, Dunworth W, Fritz-Six K & Caron KM. Receptor activity-
modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol. 
2007;21:783-796. 
30. Lenhart PM & Caron KM. Adrenomedullin and pregnancy: perspectives from animal 
models to humans. Trends Endocrinol Metab. 2012;23:524-532. 
31. Lenhart PM, Nguyen T, Wise A, Caron KM, Herring AH & Stuebe AM. 
Adrenomedullin signaling pathway polymorphisms and adverse pregnancy 
outcomes. Am J Perinatol. 2014;31:327-334. 
32. Li M, Yee D, Magnuson TR, Smithies O & Caron KM. Reduced maternal expression 
of adrenomedullin disrupts fertility, placentation, and fetal growth in mice. J Clin 
Invest. 2006;116:2653-2662. 
33. Tsatsaris V, Tarrade A, Merviel P, Garel JM, Segond N, Jullienne A & Evain-Brion D. 
Calcitonin gene-related peptide (CGRP) and CGRP receptor expression at the 
human implantation site. J Clin Endocrinol Metab. 2002;87:4383-4390. 
34. Li M, Wu Y & Caron KM. Haploinsufficiency for adrenomedullin reduces pinopodes 
and diminishes uterine receptivity in mice. Biol Reprod. 2008;79:1169-1175. 
35. Li M, Schwerbrock NM, Lenhart PM, Fritz-Six KL, Kadmiel M, Christine KS, Kraus 
DM, Espenschied ST, Willcockson HH, Mack CP & Caron KM. Fetal-derived 
adrenomedullin mediates the innate immune milieu of the placenta. J Clin Invest. 
2013;123:2408-2420. 
36. Chauhan M, Ross GR, Yallampalli U & Yallampalli C. Adrenomedullin-2, a novel 
calcitonin/calcitonin-gene-related peptide family peptide, relaxes rat mesenteric 
artery: influence of pregnancy. Endocrinology. 2007;148:1727-1735. 
37. Chauhan M, Yallampalli U, Reed L & Yallampalli C. Adrenomedullin 2 antagonist 
infusion to rats during midgestation causes fetoplacental growth restriction through 
apoptosis. Biol Reprod. 2006;75:940-947. 
92 
 
38. Chauhan M, Balakrishnan M, Yallampalli U, Endsley J, Hankins GD, Theiler R & 
Yallampalli C. Adrenomedullin 2/intermedin regulates HLA-G in human trophoblasts. 
Biol Reprod. 2011;85:1232-1239. 
39. Havemann D, Balakrishnan M, Borahay M, Theiler R, Jennings K, Endsley J, Phelps 
J, Hankins GD, Yallampalli C & Chauhan M. Intermedin/adrenomedullin 2 is 
associated with implantation and placentation via trophoblast invasion in human 
pregnancy. J Clin Endocrinol Metab. 2013;98:695-703. 
40. Dong YL, Green KE, Vegiragu S, Hankins GD, Martin E, Chauhan M, Thota C & 
Yallampalli C. Evidence for decreased calcitonin gene-related peptide (CGRP) 
receptors and compromised responsiveness to CGRP of fetoplacental vessels in 
preeclamptic pregnancies. J Clin Endocrinol Metab. 2005;90:2336-2343. 
41. Dong YL, Vegiraju S, Chauhan M, Gangula PR, Hankins GD, Goodrum L & 
Yallampalli C. Involvement of calcitonin gene-related peptide in control of human 
fetoplacental vascular tone. Am J Physiol Heart Circ Physiol. 2004;286:H230-239. 
42. Fei X, Hongxiang Z, Qi C & Daozhen C. Maternal plasma levels of endothelial 
dysfunction mediators including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia. 
Adv Clin Exp Med. 2012;21:573-579. 
43. Gangula PR, Thota C, Wimalawansa SJ, Bukoski RD & Yallampalli C. Mechanisms 
involved in calcitonin gene-related Peptide-induced relaxation in pregnant rat uterine 
artery. Biol Reprod. 2003;69:1635-1641. 
44. Knerr I, Dachert C, Beinder E, Metzler M, Dotsch J, Repp R & Rascher W. 
Adrenomedullin, calcitonin gene-related peptide and their receptors: evidence for a 
decreased placental mRNA content in preeclampsia and HELLP syndrome. Eur J 
Obstet Gynecol Reprod Biol. 2002;101:47-53. 
45. Segerer SE, Martignoni F, Bogdan A, Muller N, Kapp M, Dietl J, Rieger L & 
Kammerer U. Thrombopoietin modulates the proliferation, migration and cytokine 
profile of decidual cell subsets during early gestation. Mol Hum Reprod. 
2013;19:361-368. 
46. Lash GE, Schiessl B, Kirkley M, Innes BA, Cooper A, Searle RF, Robson SC & 
Bulmer JN. Expression of angiogenic growth factors by uterine natural killer cells 
during early pregnancy. J Leukoc Biol. 2006;80:572-580. 
47. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, 
Waugh J, Anumba D, Kenny LC, Redman CW & Shennan AH. Diagnostic accuracy 
of placental growth factor in women with suspected preeclampsia: a prospective 
multicenter study. Circulation. 2013;128:2121-2131. 
48. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, 
Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP & Karumanchi SA. 




49. Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL & Sharma S. Vascular 
endothelial growth factor C facilitates immune tolerance and endovascular activity of 
human uterine NK cells at the maternal-fetal interface. J Immunol. 2009;182:4085-
4092. 
50. Ashkar AA & Croy BA. Functions of uterine natural killer cells are mediated by 
interferon gamma production during murine pregnancy. Semin Immunol. 
2001;13:235-241. 
51. Zhou J, Xiao XM & Wu YH. Expression of interferon-gamma in decidual natural killer 
cells from women with hypertensive disorder complicating pregnancy. J Obstet 
Gynaecol Res. 2013; 
52. Wallace AE, Host AJ, Whitley GS & Cartwright JE. Decidual natural killer cell 
interactions with trophoblasts are impaired in pregnancies at increased risk of 
preeclampsia. Am J Pathol. 2013;183:1853-1861. 
53. Naruse K, Lash GE, Innes BA, Otun HA, Searle RF, Robson SC & Bulmer JN. 
Localization of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitors for 
MMPs (TIMPs) in uterine natural killer cells in early human pregnancy. Human 
Reproduction. 2009;24:553-561. 
54. Lash GE, Naruse K, Robson A, Innes BA, Searle RF, Robson SC & Bulmer JN. 
Interaction between uterine natural killer cells and extravillous trophoblast cells: 
effect on cytokine and angiogenic growth factor production. Human Reproduction. 
2011;26:2289-2295. 
55. Arck PC & Hecher K. Fetomaternal immune cross-talk and its consequences for 
maternal and offspring's health. Nat Med. 2013;19:548-556. 
56. Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol. 
2013;31:387-411. 
57. Cotechini T, Komisarenko M, Sperou A, Macdonald-Goodfellow S, Adams MA & 
Graham CH. Inflammation in rat pregnancy inhibits spiral artery remodeling leading 
to fetal growth restriction and features of preeclampsia. J Exp Med. 2014;211:165-
179. 
58. Parker VJ, Solano ME, Arck PC & Douglas AJ. Diet-induced obesity may affect the 
uterine immune environment in early-mid pregnancy, reducing NK-cell activity and 
potentially compromising uterine vascularization. Int J Obes (Lond). 2013; 
59. Lockwood CJ, Huang SJ, Chen CP, Huang Y, Xu J, Faramarzi S, Kayisli O, Kayisli 
U, Koopman L, Smedts D, Buchwalder LF & Schatz F. Decidual cell regulation of 
natural killer cell-recruiting chemokines: implications for the pathogenesis and 
prediction of preeclampsia. Am J Pathol. 2013;183:841-856. 
60. Charalambous F, Elia A & Georgiades P. Decidual spiral artery remodeling during 
early post-implantation period in mice: investigation of associations with decidual 












 The immunology of pregnancy is complex and incompletely understood.  Aberrant 
immune activity in the decidua and in the placenta is believed to play a role in diseases of 
pregnancy, such as infertility, miscarriage, fetal growth restriction, and preeclampsia.  Here, 
we briefly review the endocrine control of uterine natural killer cell populations and their 
functions by the peptide hormone adrenomedullin.  Studies in genetic animal models have 
revealed the critical importance of adrenomedullin dosage at the maternal-fetal interface, 
with cells from both the maternal and fetal compartments contributing to essential aspects 
underlying appropriate endometrial receptivity, implantation, and vascular remodeling of 
spiral arteries.  These basic insights into the crosstalk between the endocrine and immune 
systems within the maternal-fetal interface may ultimately translate to a better understanding 




 Pregnancy presents a mysterious immunological paradox that is permitted by the 
complex, unique immunology of the maternal-fetal interface.  We are only beginning to 
                                                
1Reprinted in part with permission from: Matson BC & Caron KM. Adrenomedullin and endocrine 
control of immune cells during pregnancy. Cell Mol Immunol. 2014;11:456-459. 
95 
 
understand how this very specialized immune “subsystem” differs from the systemic immune 
system and thus effectively protects the fetus from maternal rejection.  For example, the 
sizable uterine natural killer (uNK) cell and macrophage populations found during early 
pregnancy are distinctive in their cell surface markers and functions compared to their 
peripheral counterparts.1,2 Understanding the activity and control of these immune cell types 
will shed light on this immunological paradox and possibly inform the pathophysiology of 
complications of pregnancy. 
During the past decade, numerous studies have characterized critical roles for the 
peptide hormone adrenomedullin (Adm gene; AM protein) in the establishment and 
maintenance of a healthy pregnancy. Here, we discuss the effects of AM on placentation, 
concentrating on the control of the uNK cell population and its subsequent involvement in 
the process of spiral artery remodeling – a necessary process for the maternal vascular 
adaptation to pregnancy. Importantly, studies addressing the link between AM and uNK cells 
exemplify an immunological basis for preeclampsia that can be strongly modulated by the 
maternal and fetal endocrine systems. 
 
AM and Immune-based Placental Vascular Pathologies  
 Examination of Adm-/- mouse placentas and their vascular abnormalities revealed a 
direct link between fetal-derived AM and placental immunology. Notably, the placenta-
perfusing spiral arteries of Adm-/- placentas are abnormally invested with a thick layer of 
vascular smooth muscle cells at e13.5.3 By contrast, in wild type placentas from neighboring 
littermates, these vascular smooth muscle cells have undergone apoptosis during the 
process of spiral artery remodeling, which transforms the spiral arteries into large, high-
capacitance vessels associated with the migration of fetal trophoblast cells into the arteries.4  
Importantly, insufficient spiral artery remodeling has been implicated in the pathophysiology 
of preeclampsia, a hypertensive disease of pregnancy. Therefore, the preeclampsia-like 
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phenotypes of Adm-/- placentas recapitulate prior evidence of dysregulation of AM levels in 
complications of pregnancy.5 
 Because uNK cells are the largest population of decidua-specific immune cells and 
are established effectors of spiral artery remodeling, uNK cells were counted in Adm-/- 
mouse placentas and found to be fewer in number compared to wild type placentas.3 This 
reduction in uNK cell content was not associated with apoptosis but rather with under-
recruitment of uNK cells to the decidua. Ovarian transplants (Adm+/-  ovaries carrying Adm-
null germ cells were placed in wild type recipient females) further confirmed that the Adm-/- 
placental immune and vascular phenotypes were due to the loss of fetal-derived AM and 
independent of the genotype or dosage of Adm from the dam.3  This conclusion highlights a 
critical function for fetal-derived AM as an essential signal to elicit changes to the maternal 
vasculature during pregnancy.6 
 
AM Dose-dependent uNK Cell Recruitment and Signaling 
 Subsequent studies of a gene-targeted murine model of Adm overexpression (Admhi 
allele, which expresses Adm at levels three-fold higher than the wild type allele) determined 
that uNK cell recruitment to the decidua by AM is dosage-dependent.3,7 Specifically, Admhi/hi 
placentas demonstrated a 30% increase in uNK cells.3 Because the uNK cells in these 
placentas were labeled with Dolichos biflorus agglutinin (DBA) lectin, we can conclude that 
the uNK cell population that was quantified is, in fact, the one that expands during 
pregnancy.8 Debate continues about whether this uNK cell population is derived from extra-
uterine precursors that home to the uterus and differentiate in situ early in pregnancy or 
whether uNK cell precursors mature outside the uterus and then migrate to the uterus due to 
hormonal cues like AM. 
 Given the active participation of uNK cells in spiral artery remodeling as well as the 
uNK cell and vascular phenotypes of Adm-/- and Admhi/hi placentas,9 it stood to reason that 
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AM could augment the effects of uNK cells on vascular smooth muscle cells. Indeed, 
treatment of primary mouse vascular smooth muscle cells with uNK cell-conditioned media 
caused changes in cell morphology and induced apoptosis;3 these processes were 
enhanced when the uNK cell-conditioned media was supplemented with AM, suggesting 
that AM is important not only for the recruitment but also for the activation of uNK cells.3 
 uNK cells produce an array of cytokines and chemokines that engage these cells in a 
complex dialogue with trophoblast cells to execute spiral artery remodeling.9,10 Therefore, it 
was expected that the dynamic fluctuations in uNK cell population size between Adm-/- and 
Admhi/hi placentas would be mirrored by concomitant changes in the expression profile of 
these signaling molecules. Indeed, Adm-/- downregulated and Admhi/hi upregulated Ccl7, 
Ccl17, Cxcl10, Xcl1, and TNF.3 Concordantly, in vitro stimulation of isolated uNK cells by 
AM upregulated select signaling factors, including matrix metalloproteinase 9, which is 
involved in spiral artery smooth muscle cell apoptosis.3 Given the diversity of angiogenic 
factors, growth factors, and other signaling molecules that are secreted by uNK cells, it is 
plausible that there are signaling cascades other than the ones already identified that are 
regulated by AM. 
 
Future Directions 
 Collectively, these data support AM as a player in the pathophysiology of 
reproductive disorders like preeclampsia via control of the uNK cell population size and of 
trophoblast invasion into the uterine luminal epithelium and into uterine spiral arteries. While 
perturbations in the size of the uNK cell population have been implicated in a variety of 
human reproductive disorders,11,12 it has also been found that women with larger cytotoxic 
CD56dimCD16+ uNK cell populations are at a higher risk for infertility and recurrent 
pregnancy loss.13 Therefore, not only the uNK cell population size is important, but also the 
delicate balance between the peripheral blood-like, cytotoxic CD56dimCD16+ uNK cells and 
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the “true” CD56brightCD16- cytokine- and chemokine-producing uNK cells.13 As argued by 
several groups, it is premature to base clinical decisions on information about size or type of 
uNK cell populations in patients.12,14 
 It will be interesting to determine whether AM exerts endocrine control over other 
immune cell populations at the maternal-fetal interface, such as decidual macrophages. 
There is evidence that AM can confer a semi-mature phenotype to dendritic cells, which 
provide instructions to T cells, but this may be of little consequence to placental immunology 
given the paucity of dendritic cells in the decidua.15 Of course, it is also possible that other 
CGRP family peptides affect uNK cell recruitment. Adrenomedullin 2, also known as 
intermedin, has been shown to stimulate trophoblast invasion and therefore may participate 
in assemblage of the uNK cell population.16,17 
 
Concluding Remarks 
 Altogether, the aforementioned studies point to the complexity of the control of 
immune cells specific to the transient environment of the pregnant uterus.  Here, we have 
emphasized that AM is important for establishing and maintaining a successful pregnancy.  
Specifically, haploinsufficiency for AM and lack of AM confer shallow trophoblast invasion 
into the uterine luminal epithelium during implantation and into spiral arteries, respectively.  
These observations have recently been recapitulated in vitro, whereby AM stimulates 
trophoblast invasion.18  Future studies will aim to address the local control of AM dosage 
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Levels of the peptide hormone adrenomedullin (AM) are elevated during normal 
pregnancy, but whether this differs during complications of pregnancy remains unresolved. 
AM can be quantified by measuring its preprohormone byproduct, midregional pro-
adrenomedullin (MR-proADM). MR-proADM has shown prognostic value as a biomarker of 
heart failure, sepsis, and community-acquired pneumonia. Given the relevance of AM to 
pregnancy, we tested the hypothesis that MR-proADM provides a biomarker for 
preeclampsia. We find that MR-proADM plasma concentrations are blunted in severe 
preeclampsia and that MR-proADM is similarly effective as established biomarkers endoglin 




 Preeclampsia is a common pregnancy complication characterized by hypertension 
and proteinuria.1 Identification of novel serum biomarkers for this potentially dangerous 
condition is highly desirable. The peptide hormone adrenomedullin (AM) has garnered 
attention as a candidate biomarker of preeclampsia because its levels are elevated during 
                                                
1Reprinted with permission from: Matson BC, Corty RW, Karpinich NO, Murtha AP, Valdar W, 
Grotegut CA & Caron KM. Midregional pro-adrenomedullin plasma concentrations are blunted in 
severe preeclampsia. Placenta. 2014;35:780-783. 
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pregnancy2 but often altered in pregnancy complications.3 Additionally, polymorphisms in the 
ADM gene have been associated with preeclampsia.4 
 Data from AM loss- and gain-of-function mouse models support a role for AM in 
placentation. Remodeling of uterine spiral arteries, conduits of the uteroplacental circulation, 
is critical for proper placentation5 and is accomplished in part by crosstalk between uterine 
natural killer (uNK) cells and trophoblast cells of the placenta.6 Compared to wild type 
placentas, Adm-/- placentas exhibit fewer uNK cells and insufficient spiral artery remodeling.7 
Placentas from an animal model of AM overexpression (Admhi/hi)8 concordantly exhibit more 
uNK cells than wild type placentas and upregulate expression of uNK cell-secreted signaling 
molecules.7 Adm+/- intercrosses commonly produce embryos demonstrating fetal growth 
restriction and morphological abnormalities, both common consequences of placental 
disorders.9 
 These data underscore the role of AM in placentation and its potential as a 
biomarker of preeclampsia. Previous studies arrived at inconsistent conclusions about 
changes in AM levels in preeclampsia,3 likely due to the brief half-life of AM10 and its 
interaction with a binding protein.11 Recently, an assay was developed to detect midregional 
pro-adrenomedullin (MR-proADM), a cleaved byproduct of the preprohormone that is in 
direct correlation with AM.12 Here, we measured MR-proADM plasma concentrations in 
women with severe preeclampsia and compared this precursor peptide to previously 
established biomarkers of preeclampsia. 
 
Materials and Methods 
Study design and patient samples 
 The study was approved by the Institutional Review Boards of Duke University and 
the University of North Carolina at Chapel Hill. Thirty patients with preeclampsia and 30 
patients without preeclampsia delivering at Duke University Hospital with available plasma 
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samples were selected from the Pregnancy Outcomes: Blood and Tissue Repository study, 
which collected biological specimens from patients at the time of presentation and delivery. 
We subsequently limited our experimental group to women with severe preeclampsia by 
excluding women with mild preeclampsia (n=5). Additionally, women providing postpartum 
plasma samples (n=12), women carrying twin pregnancies (n=3), and smokers (n=7) were 
excluded from the original cohort. Former smokers were considered nonsmokers. 
Immunoassays 
 Endoglin and placental growth factor (PlGF) plasma concentrations were measured 
using commercial ELISA kits (R&D Systems, Minneapolis, MN) (Table 7-S1). Plasma 
samples were diluted 1:5 for endoglin and 1:2 for PlGF. MR-proADM plasma concentrations 
were measured undiluted by Phadia Immunology Reference Laboratory (Portage, MI) using 
a commercial immunofluorescent assay (B∙R∙A∙H∙M∙S KRYPTOR, Hennigsdorf, Germany) 
(Table 7-S1). 
Statistics 
 Student’s t-tests were performed in GraphPad Prism 5.0. F tests were performed in 
R. Logistic regression and ROC analysis were performed using R package glm with no 
cross validation. P values < 0.05 were considered statistically significant. 
 
Results 
 Table 7-1 summarizes the clinical characteristics of the patients whose plasma was 
analyzed in this study (Figure 7-1A). Plasma samples from controls and from women with 
severe preeclampsia were analyzed by ELISA for conventional biomarkers of preeclampsia. 
As expected,13 soluble endoglin plasma concentrations were elevated in women with severe 
preeclampsia (Figure 7-1B), and placental growth factor (PlGF) plasma concentrations were 
blunted in women with severe preeclampsia (Figure 7-1C). After confirming that plasma from 
women with severe preeclampsia adhered to conventional biomarker paradigms, plasma 
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samples were then analyzed by a sandwich immunoassay for MR-proADM. In women with 
severe preeclampsia, MR-proADM concentrations were blunted (Figure 7-1D). While plasma 
freezer storage time differed significantly between groups, storage time did not correlate 
with MR-proADM concentration (r2=0.004, data not shown). 
 To compare endoglin, PlGF, and MR-proADM as biomarkers of severe 
preeclampsia, we generated logistic regression models for each of these biomarkers alone 
and in combination. We then analyzed these models by generating receiver operating 
characteristic (ROC) curves and comparing their respective areas under the curve (AUC) 
(Figure 7-2). Based on AUCs, we concluded that, in this dataset, endoglin (AUC=0.73) and 
MR-proADM (AUC=0.69) classified patients similarly, while PlGF is slightly more informative 
(AUC=0.85). In multiple logistic regression, endoglin and MR-proADM together are better 




As predicted by the Adm-deficient mouse model,7,9,14 we found blunted MR-proADM 
plasma concentrations in women with severe preeclampsia. Interestingly, during our revision 
process, Wellmann et al. reported elevated MR-proADM in preeclampsia using a similarly 
sized cohort.15 However, their study did not distinguish between mild and severe 
preeclampsia and included two key groups of patients that we excluded from our study: 
patients carrying multiple pregnancies and smokers. Both twins and smoking have been 
shown to upregulate Adm expression, which could explain the finding of elevated AM 
plasma concentrations in their patients.16-18 
Moreover, we found that MR-proADM is similarly effective as endoglin and PlGF at 
discriminating between patients with severe preeclampsia and controls. However, as 
acknowledged as a methodology limitation in both studies, the disease prevalence is higher 
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in the study population than in the general population. Additionally, both studies collected 
plasma samples late in pregnancy, while an ideal biomarker would detect preeclampsia 
early in pregnancy before the clinical disease becomes apparent. Ultimately, the data 
presented here warrant further investigation of MR-proADM at earlier gestational ages with 





  Control (n=18) Severe PE (n=15) p val.b 
Age (years) 33.8 ± 4.5 (25-41) 28.5 ± 6.6 (21-41) 0.01 
BMI at delivery 31.4 ± 6.7 (23.2-48.6) (n=17) 38.2 ± 9.2 (25.6-54.0) 0.03 
Gravidity 3 (3-4) 2 (1-3) 0.02 
Parity 1 (1-2) 0 (0-2) 0.14 
Ethnicity    
White 12 7  
Black 3 8 0.99 
Asian 3 0 0.07 
Gestational age at delivery 
(weeks) 38.7 ± 0.8 (37.2-39.7) 33.9 ± 4.2 (27.4-39.9) <0.001 
Labor status    
Not in labor 14 10  
In labor 4 5 0.48 
Mode of delivery    
Cesarean 16 12  
Vaginal 2 3 0.48 
Blood pressure    
Systolic (mm Hg) 115.9 ± 13.1 (110-148) 164.7 ± 13.8 (143-186) <0.001 
Diastolic (mm Hg) 72.5 ± 9.1 (57-92) 103.9 ± 8.4 (90-115) <0.001 
Proteinuria    
Protein dip 0.28 ± 0.75 (0-3) 2.6 ± 1.1 (1-4) (n=10) <0.001 
Past medical history    
Hypertension 0 7  
Pregnancy-related morbidity    
Gestational diabetes 1 4 0.12 
HELLP syndrome 0 3  
Chorioamnionitis 0 1  
Birthweight (grams) 3488 ± 393 (2980-4710) 2309 ± 1191 (590-4850) <0.001 
Fetal growth restriction 0 3  
Freezer storage time (days) 426.1 ± 295.8 (133-1024) 837.2 ± 322.0 (155-1099) <0.001 
Data are presented as mean ± standard deviation (range). Gravidity and parity are presented as 
median (interquartile range). The n is provided if different from the group n due to unavailable data. 
BMI, body mass index; HELLP, hemolysis, elevated liver enzymes, low platelets. 
aStandard diagnostic criteria for severe preeclampsia were used: a systolic blood pressure ≥160 
mm Hg and/or a diastolic blood pressure ≥110 mm Hg and proteinuria  >500 mg/24 hours. 
bStudent's t-test for continuous variables, F test for categorical variables. 
 




      Control       PE       p val.a 
Endoglin (ng/mL)  16.5 ± 9.6 (2.2-32.0) (n=17)  
25.3 ± 13.1 (4.2-46.4) 
(n=12)  0.046 
PlGF (pg/mL)  317.3 ± 211.7 (15.1-784.4)  
113.4 ± 120.1 (5.9-406.4) 
(n=11)  0.007 
MR-proADM (nmol/L)   1.6 ± 0.6 (0.8-2.9)   1.2 ± 0.5 (0.3-2.0)   0.041 
Data are presented as mean ± standard deviation (range). Plasma samples that were too concentrated 
or too dilute to be detected within the range of the ELISA standard curve for endoglin and PlGF, 
respectively, were excluded from analysis. Grubbs' test detected one significant outlier in the PlGF 
concentrations in the PE group; this outlier was also excluded from analysis. 
aStudent's t-test.           
 
Table 7-2. Plasma concentrations of endoglin, PlGF, and MR-proADM in controls and 






Figure 7-1. Biomarkers of preeclampsia. (A) Patients excluded from the original 60 patient 
cohort and (B-D) plasma concentrations of (B) endoglin, (C) placental growth factor (PlGF), 
and (D) MR-proADM measured by ELISA (A, B) or sandwich immunoassay (C) in controls 
and women with severe preeclampsia (PE). Boxes extend from the 25th to the 75th percentile. 
Whiskers extend 1.5 times the interquartile range below and above the 25th and 75th 
percentiles, respectively. Horizontal lines dividing the boxes identify the median of each group. 
Significant outliers, determined by Grubbs’ test, are identified by a solid black dot and 
excluded from the analysis in this figure. Four plasma samples were too concentrated to be 
detected within the range of the endoglin ELISA standard curve; one of these samples 
belonged to the control group, while the other three belonged to the PE group. Likewise, four 
plasma samples were too dilute to be detected within the range of the PlGF ELISA standard 
curve; all four of these samples belonged to the PE group. These too-concentrated or too-
dilute samples were excluded from analysis. Groups were compared by Student’s t-test. 





Figure 7-2. ROC curves for five logistic regression models of current severe 
preeclampsia based on biomarker concentrations. Plus signs separate covariates. 
Samples that fell above (endoglin, n=4) or below (PlGF, n=5) the ELISA standard curve were 





Endoglin (R&D Systems, DNDG00) 
detection limit 0.007 ng/mL 
range 0.007 ng/mL – 10 ng/mL 
specificity No interference of the following 
recombinant proteins: human activin A, 
activin RIA, activin RIIA, activin RIIB, 
BMPR-1A, BMPR-1B, BMP-2, BMP-4, 
BMP-5, BMP-6, follistatin 288, follistatin 
300, follistatin 315, inhibin A, inhibin B, 
LAP, TGF-α, TGF-β1, TGF-β1.2, TGF-β2, 
TGF-β3, TGF-β RII, TGF-β RIII; mouse 
BMPR-1A, BMPR-1B; rat agrin; porcine 
TGF-β2; amphibian TBF-β5. 
 
No interference of the following natural 
proteins: human TGF-β1; porcine TGF-
β1. 
intra-assay coefficient of variation (CV) 2.8 – 3.2% (3 samples; n=20 replicates 
each) 
inter-assay coefficient of variation (CV) 6.3 – 6.7% (3 samples; n=40 assays 
each)  
recovery average 101% 
linearity (EDTA plasma, 1:4 dilution) average 107% of expected 
  
PlGF (R&D Systems, Catalog Number DPG00) 
detection limit < 7 pg/mL 
range < 7 pg/mL – 1000 pg/mL 
specificity No interference of the following 
recombinant proteins: human ANG, AR, 
CNTF, β-ECGF, EGF, Epo, FGF acidic, 
FGF basic, FGF-4, FGF-5, FGF-6, FGF-7, 
G-CSF, GM-CSF, sgp130, GROα, GROβ, 
GROγ, HB-EGF, HGF, IFN-γ, IGF-I, IGF-
II, IL-1α, IL-1β, IL-1 ra, IL-1 sRI, IL-1 sRII, 
IL-2, IL-2 sRα, IL-3, IL-3 sRα, IL-4, IL-4 
sR, IL-5, IL-5 sRβ, IL-6, IL-6 sR, IL-7, IL-
8, IL-9, IL-10, IL-11, IL-12, IL-13, LAP, 
LIP, M-CSF, MCP-1, MIP-1α, MIP-1β, β-
NGF, OSM, PD-ECGF, PDGF-AA, PDGF-
AB, PDGF-BB, PTN, RANTES, SCF, 
SLPI, TGF-α, TGF-β1, TGF-β3, TGF-β 
sRII, TNF-α, TNF-β, sTNF RI, sTNF RII, 
VEGF; mouse GM-CSF, IL-1β, IL-3, IL-4, 
IL-5, IL-5 sRα, IL-6, IL-7 IL-9, IL-10, IL-13, 
LIF, MIP-1α, MIP-1β, SCF, TNF-α; 




No interference of the following natural 
proteins: bovine FGF acidic, FGF basic; 
human PDGF, TGF-β1; porcine PDGF, 
TGF-β1, TGF-β2. 
 
Recombinant human PlGF/VEGF 
heterodimer cross-reacts 5%. 
 
Recombinant human PlGF-2 cross-reacts 
50%. 
 
Recombinant human VEGF R1/Flt-1/Fc 
Chimera interferes at concentrations 
greater than 2000 pg/mL. 
intra-assay coefficient of variation (CV) 2.8 – 3.2% (3 samples; n=20 replicates 
each) 
inter-assay coefficient of variation (CV) 6.3 – 6.7% (3 samples; n=40 assays 
each)  
recovery average 101% 
linearity (EDTA plasma, 1:4 dilution) average 107% of expected 
  
MR-proADM (BRAHMS Kryptor MR-proADM Assay via Phadia Immunology 
Reference Laboratory) 
detection limit 0.05 nmol/L 
range 0.05 nmol/L – 10 nmol/L 
sensitivity 0.25 nmol/L 
specificity No interference of: cTNI up to 400 ng/mL; 
myoglobin up to 852 ng/mL; CKMB up to 
204 ng/mL; PCT up to 50.2 ng/mL; MR-
proANP up to 905 pmol/L; CT-proET1 up 
to 409 pmol/L; CRP up to 110 μg/mL. 
intra-assay coefficient of variation (CV) Concentration CV 
 0.2 nmol/L – 0.5 nmol/L ≤10% 
 0.5 nmol/L – 2 nmol/L <4% 
 2 nmol/L – 6 nmol/L <2% 
 > 6 nmol/L <3.5% 
inter-assay coefficient of variation (CV) Concentration CV 
 0.2 nmol/L – 0.5 nmol/L ≤20% 
 0.5 nmol/L – 2 nmol/L ≤11% 
 2 nmol/L – 6 nmol/L ≤10% 
 > 6 nmol/L ≤6% 
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Chapter 8: Conclusions and Future Directions 
 
 
Summary of Results 
 In Chapter 7, we built upon the Caron laboratory’s past investigations into AM and 
the maintenance of pregnancy in mice by expanding our studies into clinical samples from 
human patients. Specifically, we analyzed changes in AM in women with preeclampsia, a 
hypertensive disease of pregnancy characterized by dysregulation of uNK cells and 
insufficient spiral artery remodeling in the placenta. We performed a case-control study 
using plasma samples from the Pregnancy Outcomes: Blood and Tissue Repository study at 
Duke University, initially including 30 pregnant women with preeclampsia and 30 
normotensive pregnant women. We then limited our study to women with singleton 
pregnancies with or without severe preeclampsia who did not smoke and who donated 
plasma prior to delivery.  
First, we confirmed that two of the best-available biomarkers for preeclampsia, 
soluble endoglin (sEng) and placental growth factor (PlGF), were significantly changed in 
the expected directions in our patients with severe preeclampsia. We then analyzed these 
clinical samples for mid-regional pro-adrenomedullin (MR-proADM), finding that MR-proADM 
concentrations were lower in women with severe preeclampsia – a conclusion consistent 
with the Caron lab’s AM-deficient placenta mouse model, which demonstrates 
preeclampsia-like phenotypes. Finally, we generated receiver operating characteristic (ROC) 
curves for each individual biomarker tested and then in combination with each other. We 
found that MR-proADM was similarly effective at discriminating between cases and controls 
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as sEng and PlGF and that adding information about MR-proADM to both sEng and PlGF in 




 In the late 1990s and early 2000s, several groups assessed changes in AM in 
preeclampsia using several different assays, including ELISAs and radioimmunoassays.1 
However, these groups were unable to come to a consensus on the directionality of change 
in preeclampsia. In the mid-2000s, an assay was developed to detect MR-proADM, a stable, 
proteolytically cleaved byproduct of pre-pro-AM peptide, providing hope for more consistent, 
reliable measurement of AM in human plasma.2 Given the preeclampsia-like phenotype of 
Adm null placentas,3 we were curious whether MR-proADM levels were consistently lower in 
women with preeclampsia. 
 To our knowledge, we are one of only three groups to analyze changes in MR-
proADM in preeclampsia. While we found blunted levels of MR-proADM in preeclampsia, the 
other two published studies found higher levels of MR-proADM in preeclampsia. The first, 
from Switzerland, examined a similarly sized cohort (n=27) but excluded women with a 
diagnosis of preeclampsia prior to admission and included twin pregnancies.4 The second, 
from Norway, studied a larger cohort (n=105) but did not exclude twin pregnancies.5 Neither 
of the two European studies collected data on the cigarette smoking status of study 
participants. In our study, we purposefully excluded women with multifetal gestations and 
women who smoked, because twin and triplet pregnancies have higher levels of AM than 
singleton pregnancies, and cigarette smoke upregulates AM.6-8  
In all three studies, gestational age at delivery was significantly different between 
cases and controls. Controlling for gestational age at collection and at delivery is difficult 
with small cohort sizes as well as in the absence of established reference intervals, which 
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were unavailable at the time of these studies. However, trimester-specific MR-proADM 
intervals in healthy pregnancy were published this year.9 As expected, Joosen et al. found 
that MR-proADM increases steadily throughout pregnancy and then drops precipitously in 
the postpartum period. While these trimester-specific intervals are helpful, gestational week-
specific intervals would be better and would facilitate a more informed interpretation of these 
three studies. 
It is helpful to start by assessing changes in MR-proADM during the active disease 
state, but ultimately, preeclampsia is a clinical diagnosis. Therefore, the goal of these 
biomarker studies is to identify a biomarker that can predict the development of 
preeclampsia early in pregnancy to identify patients who require higher levels of 
surveillance. To this end, we plan to perform a secondary analysis of the National Institute of 
Child Health and Human Development’s Maternal-Fetal Medicine Units Network Combined 
Antioxidant and Preeclampsia Prediction (CAPPS) trial, which concluded that vitamin C and 
E supplementation beginning in the late first or early second trimester did not affect 
preeclampsia rates.10 We have access to first, early second, late second, and third trimester 
plasma samples from 626 women in this trial and plan to measure MR-proADM 
longitudinally across pregnancy to determine if there are differences between healthy 
pregnancies and those that develop preeclampsia. It is our hope that we may be able to 
identify MR-proADM as a biomarker that can triage patients early in pregnancy, as sEng, 
soluble Flt1, and PlGF perform well late in pregnancy but cannot predict cases and controls 




 In Part II, we have highlighted the importance of uNK cell-trophoblast cell 
interactions in placentation, paying particular attention to the effects of AM on the uNK cell 
population and spiral artery remodeling and implicating AM in the pathophysiology of 
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preeclampsia. We have also drawn parallels between the Caron laboratory’s previously 
published Adm-deficient placenta mouse model and MR-proADM status in women with 
preeclampsia. Further studies on changes in MR-proADM during early pregnancy are 
necessary to determine whether MR-proADM is truly predictive of preeclampsia and can be 
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